



Review

---

# Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

---

Alessandra Musio, Federica Perazza, Laura Leoni, Bernardo Stefanini, Elton Dajti, Renata Menozzi, Maria Letizia Petroni, Antonio Colecchia and Federico Ravaioli

Special Issue

Nonalcoholic Fatty Liver Disease/Metabolic Associated Fatty Liver Disease: New Insights 3.0

Edited by

Dr. Andrea Dalbeni and Dr. Alessandro Mantovani





Review

# Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Alessandra Musio <sup>1,†</sup>, Federica Perazza <sup>1,†</sup>, Laura Leoni <sup>1,2</sup>, Bernardo Stefanini <sup>1</sup> , Elton Dajti <sup>1</sup>, Renata Menozzi <sup>2</sup>, Maria Letizia Petroni <sup>1</sup> , Antonio Colecchia <sup>3,‡</sup> and Federico Ravaioli <sup>1,3,\*</sup>

<sup>1</sup> Department of Medical and Surgical Sciences, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; alessandra.musio@studio.unibo.it (A.M.); federica.perazza@studio.unibo.it (F.P.); laura.leoni@studio.unibo.it (L.L.); bernardo.stefanini@studio.unibo.it (B.S.); elton.dajti2@unibo.it (E.D.); marialetizia.petroni@unibo.it (M.L.P.)

<sup>2</sup> Division of Metabolic Diseases and Clinical Nutrition, Department of Specialistic Medicines, University Hospital of Modena and Reggio Emilia, Largo del Pozzo 71, 41125 Modena, Italy; renata.menozzi@unimore.it

<sup>3</sup> Gastroenterology Unit, Department of Medical Specialties, University Hospital of Modena, University of Modena & Reggio Emilia, 41121 Modena, Italy; acolecch@unimore.it

\* Correspondence: f.ravaioli@unibo.it

† A.M. and F.P. contributed equally to this manuscript and shared co-first authorship.

‡ A.C. and F.R. contributed equally to this manuscript and shared co-last authorship.

**Abstract:** Chronic liver disease (CLD), including non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), affects a significant portion of the population worldwide. NAFLD is characterised by fat accumulation in the liver, while NASH is associated with inflammation and liver damage. Osteosarcopenia, which combines muscle and bone mass loss, is an emerging clinical problem in chronic liver disease that is often underappreciated. The reductions in muscle and bone mass share several common pathophysiological pathways; insulin resistance and chronic systemic inflammation are the most crucial predisposing factors and are related to the presence and gravity of NAFLD and to the worsening of the outcome of liver disease. This article explores the relationship between osteosarcopenia and NAFLD/MAFLD, focusing on the diagnosis, prevention and treatment of this condition in patients with CLD.

**Keywords:** non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; metabolic dysfunction-associated fatty liver disease; cirrhosis; advanced chronic liver disease; sarcopenia; vitamin D; osteoporosis; nutrition; chronic liver disease



**Citation:** Musio, A.; Perazza, F.; Leoni, L.; Stefanini, B.; Dajti, E.; Menozzi, R.; Petroni, M.L.; Colecchia, A.; Ravaioli, F. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease. *Int. J. Mol. Sci.* **2023**, *24*, 7517. <https://doi.org/10.3390/ijms24087517>

Academic Editor: María A. Pajares

Received: 27 March 2023

Revised: 7 April 2023

Accepted: 10 April 2023

Published: 19 April 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Non-alcoholic fatty liver disease (NAFLD), also recently named metabolic dysfunction-associated fatty liver disease (MAFLD), is the most frequent chronic liver disease—a non-infectious epidemic which burdens the healthcare system, NAFLD/MAFLD affects about 25% of the world adult population. NAFLD is increasingly considered given the involvement of the liver in metabolic syndrome. A survey reported that NAFLD is the only systematically increasing liver disease in the USA over the past three decades, associated with increased obesity and type 2 diabetes mellitus (T2DM). Furthermore, in the past two decades, the prevalence of NAFLD has increased in the Asian population due to the spread of a sedentary lifestyle, being overweight and T2DM. From histological findings, NAFLD is described as a disproportionate fat accumulation in hepatocytes, combined with insulin resistance, and is defined by steatosis in >5% of liver cells without evidence of significant hepatocyte ballooning indicative of hepatocellular damage in the absence of competing liver disease aetiologies. NAFLD may worsen and cause non-alcoholic steatohepatitis (NASH), defined by hepatic steatosis and inflammation with hepatocyte ballooning; it is possible to observe further progression to hepatic fibrosis, cirrhosis and hepatocellular carcinoma.

Osteoporosis is a bone metabolism disease in which bone becomes more fragile, and the risk of fracture following a small trauma increases since the mineral density is reduced. Sarcopenia, such as osteoporosis, is a frequent condition in the elderly and is often associated with NAFLD; sarcopenia is characterised by progressive and systemic reduction in skeletal muscle mass, strength or function, with an increased risk of disability, hospitalisation and mortality. These two conditions share several common pathophysiological pathways, among which insulin resistance; chronic systemic inflammation, particularly increased levels of inflammatory cytokines, i.e., IL-1, IL-6 and TNF- $\alpha$ ; and physical inactivity represent crucial pathophysiological elements and promote muscle and bone loss; moreover, they predict the presence and severity of NAFLD and worsen the outcome of liver disease. Interestingly, Semaglutide and Liraglutide, anti-diabetic and anti-obesity drugs, improve liver steatosis and inflammation and at the same time seem to have a positive effect on bone. In this review article, we aim to summarise the current evidence on the impact of sarcopenia and bone impairment in NAFLD/MAFLD patients and the strategy for the early identification and management of these patients. Their evaluation, management and treatment should be more appreciated in clinical practice in NAFLD patients.

## 2. Data Sources and Searches

We searched English-language publications in MEDLINE, Ovid, In-Process, the Cochrane Library, EMBASE, and PubMed until December 2022. Literature searches were performed using the following keywords: non-alcoholic fatty liver disease, NAFLD, metabolic dysfunction-associated fatty liver disease, MAFLD, chronic liver disease, advanced chronic liver disease, sarcopenia, cachexia, malnutrition, bone impairment, osteopenia and osteoporosis.

## 3. Sarcopenia

### 3.1. Definition of Sarcopenia (S) and Sarcopenic Obesity (SO)

Sarcopenia has been defined by the European Working Group on Sarcopenia in Older People as a progressive and generalised skeletal muscle disorder that increases the likelihood of adverse outcomes, including falls, fractures, physical disability and mortality [1]. According to the consensus, sarcopenia is probable when low muscle strength is detected, whereas low muscle quantity or quality confirms sarcopenia diagnosis. When low muscle strength, low muscle quantity/quality and low physical performance are all detected, sarcopenia is considered severe [1]. In clinical practice, SARC-F, a five-item questionnaire answered by patients, is recommended to screen for sarcopenia risk [2]. Table 1 summarizes the diagnostic methods proposed.

Muscle strength should be evaluated by handgrip strength (HGS) or the chair stand test (CST) [1]. HGS records the mean value (in kilograms) of three consecutive measurements of the dominant arm gripping a dynamometer [1]. The CST measures the time the patient needs to rise five times from a seated position without using their arms [1].

Low muscle strength is defined as handgrip strength (HGS) < 27 kg in men or <16 kg in women, or as a time > 15 s for five rises in the chair stand test.

To confirm the diagnosis of sarcopenia, we need to assess an alteration in muscle quantity or quality. According to the consensus mentioned above [1], magnetic resonance imaging (MRI) and computed tomography (CT) are considered to be the gold standards for non-invasive assessment of muscle quantity/mass, but dual-energy X-ray absorptiometry (DXA) and, to a lesser extent, bioelectrical impedance analysis (BIA) are mentioned as good and reliable methods to assess muscle mass [1].

CT allows quantification of the skeletal muscle area (SMA) in cm<sup>2</sup>. SMA is then adjusted to the squared height to obtain the skeletal muscle index (SMI) in cm<sup>2</sup>/m<sup>2</sup>. The lumbar skeletal muscle area correlates relatively well with the whole body muscle mass, especially at the third lumbar vertebra (L3) [3,4].

BIA is based on the whole-body electrical conductivity of hydrated tissues, allowing estimation of lean body mass through instrument-specific and population-specific regression

equations [5]. Moreover, it measures phase angle (PA), which estimates cellular membrane integrity and cellular water distribution without using a prediction equation [5].

DXA offers further advantages since it measures mass, density, total body and appendicular fat and fat-free mass [6].

When assessed by BIA or DXA, muscle quantity can be reported as total body skeletal muscle mass (SMM) or appendicular skeletal muscle mass (ASM).

Low muscle quantity is defined as appendicular skeletal mass (ASM) < 20 kg for men and <15 kg for women, or as  $ASM/height^2 < 7.0 \text{ kg/m}^2$  for men and  $<5.5 \text{ kg/m}^2$  for women.

The term sarcopenia is often used to refer only to a reduction in muscle mass, based on the sole criterion of low muscle area and utilising the skeletal muscle index (SMI): the total abdominal skeletal muscle area in  $\text{cm}^2$ , measured at the upper level of the third lumbar vertebra (L3), normalised to height ( $\text{cm}^2/\text{m}^2$ ). Sarcopenia is defined when the skeletal muscle index (SMI) is  $<41 \text{ cm}^2/\text{m}^2$  for a woman and  $<53 \text{ cm}^2/\text{m}^2$  for a man in the field of obesity [7], or  $<39 \text{ cm}^2/\text{m}^2$  for a woman and  $<50 \text{ cm}^2/\text{m}^2$  for a man in the field of end-stage liver disease (ESLD) [8].

Recently, in a joint Consensus Statement from the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO), sarcopenic obesity was defined as the co-existence of obesity and sarcopenia, diagnosed by altered skeletal muscle functional parameters and altered body composition [9]. The expert panel suggested adopting the cut-points proposed by Dodds et al. [10] (for the Caucasian population) and Chen et al. [11] (for the Asian population) for HGS and the references given by Gallagher et al. for fat mass (FM) [12], by Janssen et al. for SMM/weight [13] and by Batsis et al. for appendicular lean mass/weight (ALM/W) [14].

Myosteatosis can be considered a qualitative alteration of muscle due to fat accumulation in the muscle [15]. It is associated with an increased prevalence of NAFLD [16], with the presence and severity of NASH [17] and significant fibrosis [18].

In a cohort of 338 Korean patients with biopsy-proven NAFLD, the prevalence of severe myosteatosis was 21.1% and 33.3% in the NAFLD and early NASH groups, respectively ( $p = 0.029$ ) [19].

In a study including 675 patients with liver cirrhosis (LC) evaluated for liver transplant (LT) (23% with NASH-cirrhosis), myosteatosis was present in 52% [20]. Furthermore, in a study enrolling 265 patients listed for LT, among the 136 patients with NASH, 62% had myosteatosis [21]. In a cohort of 678 patients with LC, 77 (11.4%) had both myosteatosis and sarcopenic obesity [22].

### 3.2. The Prevalence of Sarcopenia in NAFLD and Cirrhotic-NASH and Prognosis Implication

#### 3.2.1. Sarcopenia and NAFLD

The prevalence of sarcopenia is significantly increased in NAFLD, ranging from 12.2% to 43.6% [23–29], and in NASH (about 35%) [23], compared to that in non-NAFLD patients, ranging from 8% to 9.7% [23,26]. On the other hand, some studies have identified a low prevalence of sarcopenia in NAFLD patients, ranging between 3.5% [30] and 4.5% [31]. This high heterogeneity is probably due to the differences among studies in the definition and assessment of sarcopenia, NAFLD and NASH.

Several studies have pointed out the association between NAFLD and sarcopenia. A recent meta-analysis by Cai et al. [32] included 19 studies, of which 17 were cross-sectional and only 2 were retrospective cohort studies [33,34]. The authors observed a significantly higher occurrence risk of NAFLD (OR = 1.33, 95% CI 1.20 to 1.48), NASH (OR = 2.42, 95% CI 1.27 to 3.57) and NAFLD-related significant fibrosis (OR = 1.56, 95% CI 1.34, 1.78) in subjects with sarcopenia [32].

In the two retrospective cohort studies (with 10-year [34] and 7-year follow-ups [33]), skeletal muscle mass was inversely associated with the incidence of NAFLD [33,34] and positively associated with its resolution [33].

Additional cross-sectional and retrospective studies have further confirmed the independent association between sarcopenia and NAFLD [35–42], NAFLD severity [35,37,43], fibrosis [36,40,44–47] and fibrosis severity [36,48,49].

Even if limited, prospective studies assessing the relationship between sarcopenia and NAFLD have also been conducted. In a prospective study enrolling 156 consecutive patients with biopsy-proven NAFLD and alanine aminotransferase (ALT) > 40 IU/L, 13.5% and 26.3% were diagnosed with sarcopenia with the SMI and sarcopenia index (SI; ASM-to-body mass index (BMI) ratio), respectively; in patients with hepatic fibrosis stage < 2, the SI and the skeletal muscle mass-to-body fat mass ratio were significantly higher than in patients with fibrosis stage  $\geq 2$  [50]. In another prospective study including more than 300,000 participants with a median follow-up of 10 years, lower muscle mass and grip strength were associated with a higher risk of developing severe NAFLD [51].

Furthermore, sarcopenia in NAFLD patients has been associated with adverse clinical outcomes, including a higher 10-year major osteoporotic and hip fracture probability [52], increased risk of albuminuria [53] and atherosclerotic cardiovascular disease (ASCVD) [46,54,55], and increased risk of all-cause [25,56–59], cardiovascular [25,57], diabetes-associated [25,58] and cancer-associated [58] mortality.

Conversely, some studies failed to show an association between low muscle mass and NAFLD [31] while identifying fat mass, particularly the android fat mass and the android-to-gynoid fat ratio, as a better predictor for NAFLD [31].

These studies had several limitations. First, different methods were used to assess skeletal muscle mass, such as bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA), with a few studies utilising computed tomography (CT). Furthermore, the definition of SMI varies among different studies. Most studies defined SMI as skeletal muscle mass (SMM) divided by body weight or BMI, while only a few divided SSM by height. Therefore, the definition of sarcopenia is influenced by the patient's weight, and a higher BMI may have a greater impact on the development of NAFLD than low muscle mass per se. It should be noted that, in the ESPEN and EASO consensus on sarcopenic obesity, the authors point out that a relative reduction in muscle mass in patients with high BMI and FM may have a relevant clinical and functional impact even in the absence of an absolute muscle mass reduction [9].

Adjusting muscle mass for BMI or height can lead to divergent results when evaluating the association between sarcopenia and NAFLD, as shown in a cross-sectional study including 320 participants [60].

In this study, muscle mass adjusted for BMI was associated with NAFLD diagnosed by ultrasound (US; OR, 1.71; 95% CI, 1.02 to 2.86) and comprehensive NAFLD score (CNS) (OR, 1.95; 95% CI, 1.04 to 3.65), whereas muscle mass adjusted for height was not associated with NAFLD [60].

The use of liver biopsy to evaluate NAFLD and hepatic fibrosis is another area for improvement with respect to existing studies, since this is available in only a few of them.

Third, because most studies focused on the Asian population, the findings are not widely applicable.

Altered muscle quality, identified as lower muscle attenuation or density, has been associated with prevalence of NAFLD [16], development of NASH [19,59], liver stiffness [18] and fibrosis progression [19]. In research including 9545 participants, the participants with NAFLD and adverse muscle composition (AMC), defined as low muscle volume and high muscle fat, had a 2.1-fold and 3.3-fold higher prevalence of type 2 diabetes and coronary heart disease ( $p < 0.001$ ), respectively, compared with those without AMC [27]. On the other hand, in a cross-sectional study of 45 NAFLD patients, the muscle fat fraction (MFF) was not correlated with the hepatic fat fraction ( $r = -0.035$ ,  $p = 0.823$ ) and did not significantly differ between subjects with or without significant fibrosis [61].

Studies have also examined the relationship between NAFLD patients' muscle strength and physical performance assessment. Cross-sectional studies have detected an association between lower muscle strength, NAFLD and liver fibrosis severity [37,62–66], and the asso-



ciation between SMM and NAFLD has also been investigated in children and adolescents. In a case–control study including 53 paediatric patients with NAFLD and 73 controls aged 9–15 years, the skeletal muscle-to-body fat ratio, assessed by BIA, was significantly lower in individuals with NAFLD than in those without (0.83 vs. 1.04,  $p = 0.005$ ), even after adjusting for age, sex, BMI and serum glucose [67]. Low muscle mass was associated with an increased risk for NAFLD in overweight/obese youths [68]. Furthermore, SMI and AMI were negatively associated only with steatosis in obese adolescents, without being associated with NAFLD activity score (NAS), lobular inflammation, ballooning scores or fibrosis stage [69].

### 3.2.2. Sarcopenia and NASH Liver Cirrhosis (LC)

Sarcopenia prevalence in patients with liver cirrhosis (LC) of different aetiologies (prevalence of cirrhotic NASH not specified) varies between 21.7% and 76% [70–78]. In studies involving patients with LC of different aetiologies and with a prevalence of NASH/NAFLD ranging from 9.8% to 34.5%, sarcopenia prevalence varies from 19.8% to 48% [79–81]. In a meta-analysis of 22 studies involving 6965 patients [82], the pooled prevalence of sarcopenia in patients with LC was 37.5% overall (95% CI 32.4–42.8%) and was higher in males, those with alcohol-associated liver disease, those with Child–Pugh grade C and when sarcopenia was defined by L3-SMI (i.e., assessed with the third lumbar skeletal muscle index) [82,83], independently of the model for end-stage liver disease score (MELD) [83]. A meta-analysis of 20 studies (7 Asian and 13 Western) estimated a prevalence of sarcopenia in LC patients of 48.1%, with a higher rate in men (61.6%) than in women (36%) [84].

Sarcopenia prevalence appears to increase along the different Child–Pugh stages (CPS) (18.2% in CPS A, 42.4% in CPS B and 90.5% in CPS C) [85], and after autoimmune hepatitis-related cirrhosis (80%), NASH-related LC is highest (61.9%) [85].

In patients with LC, sarcopenia has been associated with reduced quality of life [85,86]; increased risk of LC complications, such as ascites [76,87–90], hepatic encephalopathy (HE) [20,87,88,91–99], HCC [76,100–102], variceal bleeding [88], spontaneous peritonitis [76], infections [76], more extended hospital stays [76,103,104], higher hospital costs [103,104], higher 30-day readmission [76] and overall increased mortality [78,82,89,92,103–112]; as well as reduced survival [76,81,113–117]. As shown in a meta-analysis including 20 studies, LC patients with sarcopenia had poorer survival rates and an increased risk of complications, such as infection, than those without sarcopenia [84].

Moreover, myosteatorosis has been associated with higher mortality in LC patients [22, 107,118] and with the risk of developing HE in LC patients [20,119], but not with the length of hospital stay in patients with decompensated cirrhosis [120].

Recently, when body composition features, such as sarcopenia and myosteatorosis, were integrated with the model for end-stage liver disease (MELD) [121–124] and Child–Turcotte–Pugh score (CTP) [125], they increased the accuracy of this model in predicting mortality [121–124] and hospital readmission [125], particularly in those with compensated advanced chronic liver disease [126].

### 3.2.3. Sarcopenia and Liver Transplant (LT)

In a meta-analysis including 3.803 patients on waiting lists (WLs) or undergoing liver transplantation (LT), van Vugt et al. [83] reported a sarcopenia prevalence ranging from 22% to 70% [83]. Sarcopenia has been associated with WL [83,127,128], post-LT mortality [83,129–132] and with post-LT complications [73,130,131,133,134]. Only a few studies found no association between sarcopenia and post-LT mortality [73,134,135].

In patients with LC of different aetiologies, the prognostic value of myosteatorosis seems to be particularly important in the early post-operative phase, with higher rates of deaths due to respiratory and septic complications [136]. Furthermore, low muscle quality was a statistically significant predictor of an increased risk for WL mortality, with an HR of 9124 (95% CI 2871–28,970) [128].

Most studies regarding the influence of sarcopenia on transplant-related outcomes involved patients with different aetiologies of chronic liver disease (CLD). In a study including 265 patients evaluated for their first LT, of whom 126 had a primary diagnosis of NASH and 129 of alcoholic liver disease (ALD), patients with NASH had a significantly lower prevalence of sarcopenia (22% versus 47%;  $p < 0.001$ ) when compared with patients with ALD, which was not associated with LT complications [21]. A retrospective single-centre study including 146 adult patients who received LT for NASH-LC, which evaluated the association between sarcopenia and clinical outcomes, did not observe any significant difference between patients with or without sarcopenia in the length of hospitalisation following LT, re-hospitalisation in the first year post-LT, or one-year or overall survival [137].

#### 3.2.4. Sarcopenic Obesity and NAFLD

Several studies have related sarcopenic obesity (SO) to NAFLD. In a multicentre, retrospective study involving 23,889 NAFLD subjects, SO prevalence was 12.0% (2872 pts.) [138].

However, the current evidence shows high heterogeneity in the SO definitions, including increased waist-to-calf ratio [139], reduced skeletal muscle mass-to-visceral fat area ratio (SV ratio) [140–142], increased visceral fat area-to-appendicular muscle mass ratio (VAR) [143] or reduced appendicular skeletal muscle mass-to-visceral fat area ratio [144], the combination of low skeletal muscle mass or myosteatosis with visceral adiposity [48], and the combination of low muscle mass and strength with obesity defined in terms of BMI or waist circumference [39]. Surrogate markers of sarcopenic obesity were independently associated with a higher risk of NAFLD [39,139,141,143], NASH [144] and significant fibrosis [48,139] than the two components (sarcopenia and obesity) alone [39]. In a retrospective study involving 92 patients with NAFLD followed up for a median of 4.1 years, patients with a worsened SV ratio had higher liver stiffness and fat accumulation [140]. In a post hoc analysis of the ATTICA study (2020 patients completed the follow-up), participants with low SMI and abnormal waist circumference exhibited the highest NAFLD rate compared to those with moderate/high SMI and normal waist circumference (60.5% and 24.3%, respectively;  $p < 0.001$ ) [55].

In a few studies, SO was diagnosed as a combination of low muscle mass and an increased percentage of fat mass [145,146]. SO was associated with lean NAFLD [145], a higher risk of NAFLD [146] and significant liver fibrosis [146].

In a multicentre, retrospective study involving 23,889 NAFLD subjects, Chun et al. [138] validated a model of high-risk and low-risk SO, which included SI (total ASM (kg)/body mass index), age, sex, and presence or absence of metabolic syndrome. After full adjustment, high-risk SO subjects had a significantly higher risk for significant liver fibrosis or atherosclerotic cardiovascular disease (ASCVD). After a median follow-up of 3 years, the cumulative incidences of significant liver fibrosis ( $F \geq 2$ ), CVD, cirrhosis and all-cause mortality were significantly higher in high-risk SO subjects [138].

#### 3.2.5. Sarcopenic Obesity and LC

Studies have reported an SO prevalence in LC of 20% to 35% [22,115,147–150].

Among LC aetiologies, NASH has been established as an independent predictor of SO [148].

As reported in a meta-analysis including retrospective cohort studies and 1315 pre-LT patients (with a percentage of NASH as aetiology ranging from 4% to 22%), SO prevalence varied from 13% to 33% [151]. Moreover, SO increased overall mortality compared to non-SO at short- (1 year), intermediate- (3 years) and long-term follow-up (5 years), with RRs of 2.06 [95% CI: 1.28–3.33], 1.67 [95% CI: 1.10–2.51] and 2.08 [95% CI: 1.10–3.93], respectively [151]. In other studies involving patients with LC, sarcopenic obesity worsened the prognosis in Child–Pugh A patients [115] and increased post-transplant mortality [152].

**Table 1.** Methods to assess sarcopenia in patients with chronic liver disease and NAFLD.

Methods	Procedure	Units	Cut-Offs Proposed in NAFLD	Cut-Offs in LC	Pros	Cons
SARC-F	5-item questionnaire self-reported by patients	NA	NS	≥4 [153]	Inexpensive; simple; repeatable; high specificity	Subjective Low sensitivity
HGS	Records the mean value of three consecutive measurements of the dominant arm gripping a dynamometer	kg	M: <29 for BMI ≤ 24 kg/m <sup>2</sup> , ≤30 kg for BMI 24.1–28 kg/m <sup>2</sup> , ≤32 kg for BMI > 28 kg/m <sup>2</sup> , F: ≤17 kg for BMI ≤ 23 kg/m <sup>2</sup> , ≤17.3 kg for BMI 23.1–26 kg/m <sup>2</sup> , ≤18 kg for BMI 26.1–29 kg/m <sup>2</sup> , ≤21 kg for BMI >29 kg/m <sup>2</sup> [31] M: <26; F: <18 [26,154]	M: <26 F: <18 [155]	Simple and inexpensive High sensitivity	Low specificity Not representative of overall sarcopenia
SMI by CT	Total abdominal skeletal muscle area in cm <sup>2</sup> , measured at the upper level of the third lumbar vertebra (L3), normalised to height	cm <sup>2</sup> /m <sup>2</sup>	M: <50 F: <39 [48] Expressed as total muscle area/BMI M: <8.37 F: <7.47 [156]	M: <50 F: <39 [8] M: <42 F: <38 [155] M: <44.77 F: <32.50 [75]	Accurate; rapid	Radiation exposure, not available at the bedside, varying cut-points/sites of measurement and not easily repeatable
PMA	The sum of the areas of the two psoas at the level of the third or fourth lumbar vertebra	mm <sup>2</sup>	/	M: <1561 F: <1464 [114]	Accurate; no specific software is needed	Not representative of overall sarcopenia
PMI	Total bilateral psoas muscle area at the middle of the third lumbar vertebra (L3) level (cm <sup>2</sup> ), shown by CT and height (m)	cm <sup>2</sup> /m <sup>2</sup>	/	M: <5.1 F: <4.3 [157] M: <5.16 F: <4.54 [125]	Simple and commonly used	Not representative of overall sarcopenia
PDI	The ratio of the measured PMA to the estimated peak PMA, which represents the peak value of the PMA in healthy individuals	/	/	<0.75	Accurate; no specific software is needed	Not representative of overall sarcopenia



Table 1. Cont.

Methods	Procedure	Units	Cut-Offs Proposed in NAFLD	Cut-Offs in LC	Pros	Cons
PMTH	Psoas mass thickness, measured on CT at the level of the umbilicus, normalised by division by height	mm/m	NS	M: <17.3 F: <10.4 [158]	Easy to calculate	The level of the umbilicus may vary if ascites is present Not representative of overall sarcopenia
MRA	Assessed as the mean density (HU) of the entire measured cross-sectional muscle area at L3, measured on CT	HU	<42.57 HU if BMI $\geq$ 25 <39.77 if BMI < 25 [48]	M: <33 F: <28 [118]	Indicative of muscle quality	No consensus regarding use in clinical practice
FFMA	Total erector spinae muscle area and the intramuscular fat tissue measured and subtracted on MRI at the level of the radix of the superior mesenteric artery	mm <sup>2</sup>	/	M: <3197 F: <2895 [159]	Indicative of muscle quality Easy to identify Very low inter-reader variability	No consensus regarding use in clinical practice High cost Limited availability
TPMT	Greatest transverse diameter of the right psoas muscle perpendicular to the long axis (anterior–posterior oblique) of the psoas muscle diameter at the cranial L3 vertebra endplate, measured by MRI and normalised by height	mm/m	/	M: <12 F: <8 [109]	Rapid Reproducible Excellent inter- and intra-reader agreement No contrast needed	High cost Limited availability Further validation needed

Table 1. Cont.

Methods	Procedure	Units	Cut-Offs Proposed in NAFLD	Cut-Offs in LC	Pros	Cons
SMI by DEXA	Percentage of total skeletal muscle mass obtained by DXA, normalised by weight	%	M: <39.8 F: <34.1 [160]	/	Easy; reproducible; whole body	Radiation Influenced by water retention
ASM	Summing of the muscle mass of the upper and lower limbs obtained by DXA and normalised by height	Kg/m <sup>2</sup>	M: ≤7 F: ≤5.4 [26,145,154] M: ≤7.25 F: ≤5.67 [31,62]	M: <7.26 F: <5.45 [70,161,162] M: <7 (+HGS < 25 kg) [163] M: <7 F: <5.5 [164]	Easy; reproducible	Radiation Water retention may cause an overestimation of the fat-free mass
ASM (%)	Summing of the muscle mass of the upper and lower limbs obtained by DXA and normalised by weight	%	M: <32.2 F: <25.5 [165]		Easy; reproducible	Radiation Water retention may cause an overestimation of the fat-free mass
SI	Summing of the muscle mass of the upper and lower limbs obtained by DXA and normalised by BMI		M: <0.789 F: <0.521 [29] M: <0.789 F: <0.512 [25] M: <0.678 F: <0.468 [166]		Easy; reproducible	Radiation Water retention may cause an overestimation of the fat-free mass
ULMMI	Muscle mass of the upper limb obtained by DXA and normalised by height	Kg/m <sup>2</sup>		M: <2.1 F: <1.5 [167]	Easy, reproducible and less influence on water retention	Radiation
SMI by BIA	Summing of the muscle mass of the upper and lower limbs obtained by BIA and normalised by weight	%	M: ≤30.6 [168] M: ≤37; F: ≤28 [28,36,169] M: ≤30; F: ≤26.8 [170] M: <29; F: <22.9 [23,45] M: <29.1; F: <23 [171]		Safe, rapid, widely available, minimal to moderate training, repeatable and portable	Influenced by hydration status and by weight; estimates are instrument- and population-specific

Table 1. Cont.

Methods	Procedure	Units	Cut-Offs Proposed in NAFLD	Cut-Offs in LC	Pros	Cons
SMI by BIA	Summing of the muscle mass of the upper and lower limbs obtained by BIA and normalised by height	Kg/m <sup>2</sup>	M: <7.0 F: <5.7 [50,172] M: <10.76 F: <6.75 [169]		Safe, rapid, widely available, minimal to moderate training, repeatable and portable	Influenced by hydration status and by weight; estimates are instrument- and population-specific
SI by BIA	Summing of the muscle mass of the upper and lower limbs obtained by BIA and normalised by BMI	/	M: <0.789 F: <0.512 [45,171] M: <0.789 F: <0.521 [50]		Safe, rapid, widely available, minimal to moderate training, repeatable and portable	Influenced by hydration status and by weight; estimates are instrument- and population-specific
PA by BIA	The ratio of resistance (intracellular and extracellular resistance) to reactance (cell-membrane-specific resistance) expressed as an angle	°	≤5.05 [173] M: ≤5.6 F: ≤5.4 [174]		Good reliability, even in patients with fluid retention	
Right thigh muscle thickness by US	Marking of points 1/3 and 1/2 of the total distance from the top of the patella to the iliac crest. Two readings at each point: one with compression of the probe and the other without; both points averaged and corrected for height	cm/m <sup>2</sup>	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Operator-dependent No established cut-offs
Rectus abdominis thickness by US	The thickness of each rectus abdominis at about 3 cm laterally from the umbilicus, between the anterior and posterior fascial borders, applying minimal pressure	mm	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Operator-dependent No established cut-offs

Table 1. Cont.

Methods	Procedure	Units	Cut-Offs Proposed in NAFLD	Cut-Offs in LC	Pros	Cons
SI by BIA	Summing of the muscle mass of the upper and lower limbs obtained by BIA and normalised by BMI	/	M: <0.789 F: <0.512 [45,171] M: <0.789 F: <0.521 [50]		Safe, rapid, widely available, minimal to moderate training, repeatable and portable	Influenced by hydration status and by weight; estimates are instrument- and population-specific
PA by BIA	The ratio of resistance (intracellular and extracellular resistance) to reactance (cell-membrane-specific resistance) expressed as an angle	°	≤5.05 [173] M: ≤5.6 F: ≤5.4 [174]		Good reliability, even in patients with fluid retention	
Right thigh muscle thickness by US	Marking of points 1/3 and 1/2 of the total distance from the top of the patella to the iliac crest. Two readings at each point: one with compression of the probe and the other without; both points averaged and corrected for height	cm/m <sup>2</sup>	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Operator-dependent No established cut-offs
Rectus abdominis thickness by US	The thickness of each rectus abdominis at about 3 cm laterally from the umbilicus, between the anterior and posterior fascial borders, applying minimal pressure	mm	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Operator-dependent No established cut-offs

Table 1. Cont.

Methods	Procedure	Units	Cut-Offs Proposed in NAFLD	Cut-Offs in LC	Pros	Cons
Psoas muscle thickness by US	Maximum distance between the anterior and the posterior borders of the psoas muscle, perpendicular to the longitudinal fibres at a level slightly above the iliac crest	mm	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Difficult identification because of bowel gas and ascites Operator-dependent No established cut-offs
US-PTHR	Average of three measurements of the largest right psoas muscle diameter divided by height	mm/m	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Operator-dependent No established cut-offs
US-PMI	$\pi \times$ psoas radius square divided by the patient's height square	cm <sup>2</sup> /m <sup>2</sup>	/	/	Safe, rapid, accessible and repeatable Used to assess both muscle quantity and quality	Operator-dependent No established cut-offs

BIA, bioelectrical impedance analysis; HGS, handgrip strength; HU, Hounsfield units; MRA, muscle radiation attenuation; MRI, magnetic resonance imaging; NA, not applicable; NS, specific cut-offs not available; PA, phase angle; PDI, psoas depletion index; PMI, psoas muscle index; SMI, skeletal muscle index; SMM, skeletal muscle mass; LBM, total lean body mass; PMTH, psoas muscle thickness by height; US-PTHR, ultrasound psoas-to-height ratio; US-PMI, ultrasound psoas muscle index.



### 3.3. Diagnosis and Clinical Assessment of Sarcopenia in NAFLD and LC

SARC-F, the most-used tool to screen for sarcopenia risk, has low sensitivity and positive predictive value in patients with CLD [153], but when combined with HGS and the calf circumference or finger-circle test (i.e., the determination of whether or not the maximum non-dominant calf circumference is bigger than the individual's finger-ring circumference, which is formed by the thumb and forefinger of both hands) it is a valuable screening method for sarcopenia [153]. As regards the assessment of muscle strength, contrary to the CST, low HGS has been associated with NAFLD presence [37,63–66] and severity [37,63,64] and with the presence of advanced liver fibrosis [65]. Furthermore, low HGS predicts a poor clinical outcome [175] and mortality [161,176] in patients with LC. Therefore, as suggested by De et al. [177], because of its high sensitivity and low specificity, HGS may be used as a screening to stratify CT-based assessment of sarcopenia [177]. In 2016, the Japan Society of Hepatology suggested cut-offs of under 18 kg for women and 26 kg for men with LC [155].

As mentioned above, CT is the gold standard for assessing liver disease muscle quantity. It can distinguish between fluids and soft tissues [178], such as MRI [179]; therefore, it is not influenced by ascites or fluid overload, which is common in patients with LC. On the other hand, both BIA [180] and DXA [181,182] are affected by fluid overload. Furthermore, CT is a routine part of LC follow-up in most centres to screen for HCC [183].

Different definitions of mass muscle reduction have been proposed. Carey et al., in a multicentre American study in patients with end-stage liver disease, suggested SMI cut-offs of  $<50 \text{ cm}^2/\text{m}^2$  for men and  $<39 \text{ cm}^2/\text{m}^2$  for women based on optimal correlation with survival outcomes [8]. These cut-offs have been incorporated into the European Association for the Study of Liver (EASL) Clinical Practice Guidelines on nutrition in chronic liver disease [184]. Unfortunately, these criteria may not apply to all ethnic groups [185,186]. Therefore, the Japan Society of Hepatology has successively proposed different cut-offs:  $38 \text{ cm}^2/\text{m}^2$  for women and  $42 \text{ cm}^2/\text{m}^2$  for men [155]. Zeng et al. [75] have established the following cut-offs for Chinese LC patients:  $44.77 \text{ cm}^2/\text{m}^2$  in male patients and  $32.50 \text{ cm}^2/\text{m}^2$  in female patients.

Some authors have suggested measuring the dimensions and surface area of the major psoas muscle since this does not require dedicated software. The proposed measures for patients with LC include psoas muscle area (PMA), the sum of the areas of the two psoae at the level of the third or fourth lumbar vertebra, with a cut-off of  $1561 \text{ mm}^2$  in men and  $1464 \text{ mm}^2$  in women [114]; the psoas muscle thickness per height (PMTH) at the umbilical level, with a cut-off of  $17.3 \text{ mm}/\text{m}$  in men and  $10.4 \text{ mm}/\text{m}$  in women [158]; and the psoas depletion index (the ratio of the measured PMA to the estimated peak PMA, which represents the peak value of the PMA in healthy individuals), with a cut-off value of 0.75 [187].

Unfortunately, some authors have pointed out the poor performance of the psoas muscle index (PMA adjusted to the squared height—PMI) in identifying patients with increased mortality risk [157].

Altered muscle quality can also be identified through CT; muscle radiation attenuation (MRA) expressed in Hounsfield units (HU) measures muscle quality, which is inversely related to muscle fat content and quality. The proposed cut-offs to identify myosteatosis for the density of the cross-sectional muscle area at L3 are less than 33 and 28 HU in males and females, respectively [118].

MRI is often available in patients with LC, too. Indeed, it is increasingly used in CLD for specific medical scenarios, such as accurately detecting hepatocellular carcinoma (HCC) [188]. Furthermore, MRI is considered an interesting tool for evaluating body composition because of the lack of radiation exposure and the possibility of obtaining high-quality images, including information on muscle quality as evidenced by fat infiltration [189].

L3 single-slice imaging was the most accurate method used to estimate full-body skeletal muscular area and adipose tissue via MRI [190], with excellent concordance with CT [191]. In a retrospective single-centre study including 265 patients with CLD, sar-

copenia was defined by height-adjusted and gender-specific cut-offs as transverse psoas muscle thickness  $<8$  mm/m in women and  $<12$  mm/m in men [109]. MRI has also been investigated to detect muscle quality, evaluated as fat-free muscle area (the subtraction of the intramuscular fat tissue area from the total erector spinae muscle area) [159] or as an apparent diffusion coefficient [192].

Whole-body dual-energy X-ray absorptiometry (DXA) represents a method with lower cost and radiation than CT [193]. DXA cannot be used to assess muscle mass repeatedly since it exposes patients to ionising radiation. Some authors have pointed out a weak correlation between DXA and CT in LC patients [70,161]. Its major limitation is the tendency to underestimate sarcopenia in the case of fluid retention, which is common in patients with LC. Therefore, Belarmino et al. [163] proposed the measurement of appendicular skeletal muscle index (ASMI), which was not influenced by ascites or lower limb oedema [163]. In other studies, lean arm mass used to reduce the effect of lower limb oedema was superior to ASMI in predicting mortality in LC patients [162,164,167].

The use of BIA in decompensated LC is controversial because of the possible overestimation of muscle mass due to extracellular fluid overload. Therefore, researchers have tried to develop methods to assess muscle mass that are radiation-free and can be easily performed at the patient's bedside, such as ultrasonography (US) and BIA. In NAFLD, sarcopenia, assessed by BIA, is defined as a skeletal muscle mass index of  $\leq 37$  in males and  $\leq 28$  in females [28], which correlates with clinical outcomes in adults [28] and with MRI in children [194]. Otherwise, in patients with LC, the proposed cut-offs for SMI are  $<7.0$  cm<sup>2</sup>/m<sup>2</sup> for males and  $<5.7$  cm<sup>2</sup>/m<sup>2</sup> for female patients [172]. Pirlich et al. [195] highlighted a low agreement between body cell mass (BCM) estimated by BIA and BCM derived from total body potassium counting, which was the gold standard for assessing body composition [195]. Subsequently, Luengpradidgun et al. [196] compared BIA with CT, showing a fair correlation between the two measures ( $r = 0.54$ ;  $p < 0.002$ ).

On the other hand, in a study involving 122 male patients with LC, phase angle (PA) values  $\leq 5.05^\circ$  were able to predict the diagnosis of sarcopenia with high sensitivity [173]. Furthermore, in a study by Ruiz Margàin et al. [174], PA was independently associated with mortality in compensated cirrhosis, and its prognostic accuracy was not influenced by the presence of ascites [174].

The US allows the measurement of cross-sectional areas, muscle thickness and echo intensity. US measures, such as right thigh muscle thickness [197], rectus abdominis thickness (RA) [198] and psoas muscle diameter-to-height ratio [199], have been correlated with CT diagnosis [197], survival [198] and mortality [199], respectively. By contrast, psoas muscle thickness had no predictive value [198]. However, in a subsequent cross-sectional study on 42 patients with LC [200], ultrasound muscle thickness did not offer an advantage over traditional bedside techniques, such as mid-upper arm muscle circumference (MUAMC) and bioelectrical impedance spectroscopy (BIS), when compared to a reference measurement of body cell mass derived from a multi-compartment model using isotope dilution tests and DXA [200].

Different studies have shown the prognostic value of muscle performance measures in LC, such as gait speed [201], the short physical performance battery [202] and the 6 min walking test [203]. Table 1 summarises the different methods available for sarcopenia screening and diagnosis.

### 3.4. Prevention and Treatment of Sarcopenia in NAFLD/Cirrhotic-NASH Patients

Since NAFLD and sarcopenia share risk factors and pathological mechanisms, a similar therapeutic choice based on lifestyle modification as a first-line approach is warranted. The treatment of the two pathologies must take place with a common approach based, first and foremost, on lifestyle modification.

### 3.4.1. Diet

In overweight/obese NAFLD patients, moderate weight loss (<5%) is needed to improve hepatic steatosis; weight loss of 7–9% to improve histological features, such as steatosis, ballooning and inflammation; and weight loss >10% to improve fibrosis [204]. In lean patients with NAFLD, a modest weight loss of 3–5% is suggested, too [205]. The first treatment involves a hypocaloric diet (a daily reduction of 500–1000 kcal) associated with increased physical activity. The exclusion of NAFLD-promoting components (processed food and beverages high in added fructose) and a macronutrient composition adjusted according to the Mediterranean diet is also recommended. To prevent muscle mass loss, patients on the hypocaloric diet should receive a daily amount of protein of 1.2 g/kg/adjusted for ideal body weight [206], since lower protein intake has been related to a higher risk of sarcopenia [24], whereas higher protein intake in the context of energy restriction in individuals with obesity led to an attenuated loss of fat-free mass despite a more pronounced total body weight loss [207]. In NAFLD/NASH patients with sarcopenia, at least 1.2 and up to 1.5 g/kg actual body weight/day (ABW/d) dietary protein should be provided [206]. Protein provision of 1.2–1.4 g/kg ABW/d has been shown to prevent mass muscle reduction or increase muscle mass and strength in older and middle-aged women [208,209].

According to ESPEN guidelines, patients with LC should introduce 30–35 kcal/kg/day and 1.2–1.5 g/kg/day of proteins [204]. Guidelines also advise eating three meals and three snacks daily, including a late evening snack, to reduce night starvation [204].

### 3.4.2. Exercise

It must be emphasised that exercise is essential for preventing and treating sarcopenia independently of weight loss [210,211]. Both aerobic and resistance training positively impact muscular mass, function and insulin sensitivity; however, resistance training is more effective in increasing muscle mass and strength [212], and it can attenuate the muscle mass and weight loss associated with calorie restriction [213,214]. On the other hand, being physically active contributes to the long-term maintenance of weight loss [215–217] and reduction in liver steatosis [218,219], even in the absence of weight loss [218]. Sarcopenia is inversely associated with physical activity levels in patients with NAFLD [25]. In a multicentre, retrospective study involving 11,690 NAFLD subjects, increased physical activity was significantly associated with a reduced risk of fibrosis, sarcopenia and ASCVD. In subjects with sarcopenic obesity or lean NAFLD, physical activity was also independently associated with a reduced risk of fibrosis and ASCVD [220]. In a systematic review and meta-analysis including seven RCTs enrolling patients with NAFLD and sarcopenia, physical function improved with endurance or combined training, but no evidence of improvement in muscle mass was seen. However, none of these studies evaluated muscle strength [221]. Therefore, even if epidemiological studies have confirmed an inverse association between physical activity and sarcopenia in patients with NAFLD, more studies are needed to delineate its role in improving muscle mass and strength.

Unlike non-cirrhotic NAFLD, the role of physical activity in improving body composition and physical performance in LC is emerging.

In a randomised clinical trial involving twenty-three cirrhotic patients, a 12-week exercise programme, compared to a relaxation programme, led to an increase in lean body mass assessed by DXA and an improvement in the cardiopulmonary exercise test and the Timed Up&Go test, whereas no changes were observed in the relaxation group [222]. Furthermore, in a randomised controlled trial including 39 outpatients with cirrhosis, patients who underwent 12 weeks of supervised progressive resistance training increased muscle strength and size and improved general performance measures compared with control subjects [223].

In a systematic review including 22 controlled trials and five single-arm interventions with small sample sizes ( $n = 6$ –120), the role of long-term (at least eight weeks) combined diet and exercise (high protein diets with aerobic and or resistance exercises) in improv-

ing body composition in LC patients has emerged. After reviewing eleven studies, the most effective physical activity protocol combines aerobic and resistance exercise with a minimum duration of 12 weeks, as noted by Williams et al. [224]. Work to 60–80% of maximal heart rate or VO<sub>2</sub> peak is needed to significantly improve aerobic capacity [225–227]. Home-based physical programs can also improve physical performance, as shown by two small studies involving LC patients [228,229].

On the other hand, in a meta-analysis including four RCTs with 81 patients affected by end-stage liver disease, adapted physical activity proved safe, but no significant increase in muscle diameter, 6 min walking distance or VO<sub>2</sub> peak changes were observed after exercise, probably due to the small sample size [230].

In conclusion, even if the existing literature has suggested the role of physical activity in improving sarcopenia in LC patients, additional studies with larger sample sizes are needed for confirmation.

### 3.4.3. Supplementation

Branched-chain amino acids (BCAAs)—valine, leucine and isoleucine—are present in approximately 30–40% of muscle proteins and are involved in their synthesis; leucine especially stimulates protein synthesis through the mTOR pathway [231]. Furthermore, supplementation with BCAAs activates cell signalling pathways that increase myofibrillar protein synthesis [232]. Therefore, BCAA supplementation has been evaluated as a treatment for sarcopenia in LC patients. In a randomised, open-label, placebo-controlled study including 106 patients with LC and sarcopenia, treatment with BCAA for 24 weeks significantly improved muscle strength, function and muscle mass [233]. On the other hand, in a double-blind, randomised, placebo-controlled trial including 60 patients, BCAA, in addition to a home-based exercise program, did not significantly improve SMI, HSM or 6 m gait speed when compared to placebo [234].

A recent meta-analysis, including 11 studies (4 with an interventional study design, 5 with a prospective design and 5 with a retrospective design) and more than a thousand patients, evaluated the effect of BCAA supplementation on sarcopenia in LC patients [235]. The analysis revealed a significant increase in SMI and mid-arm muscle circumference (MAMC) when comparing baseline and post-intervention values. On the other hand, the increase in HGS and the decrease in triceps subcutaneous fat were insignificant. MAMC did not significantly increase when BCAA was compared to maltodextrin supplementation. Another recent systematic review, with only partial overlap of studies, highlights supplementary BCAAs when added to diet or exercise [236]. However, studies found high heterogeneity in BCAA dosage (6 to 110 g/day) and supplementation duration (3 to 12 months). Therefore, more research is needed to define the BCAA dosage and timing to prevent/treat sarcopenia in CLD patients, including the optimal combination of BCAA and resistance training to maximise the effect on muscle mass and function [237].

Beta-hydroxy-beta-methyl butyrate (HMB) is a leucine metabolite that can potentially increase muscle mass and performance by stimulating protein synthesis and reducing muscle catabolism. Two small, randomised trials exploring the role of HMB supplementation in LC patients led to conflicting results. In the first randomised, single-blind, placebo-controlled trial including 24 patients with LC, a dose of 3 g/day was administered for 12 weeks, with a significant increase in muscle function and quadriceps muscle mass measured by ultrasound and without adverse events [238]. In another randomised, controlled, double-blind trial including 43 subjects with LC, adding three g/day of HMB to the diet did not change fat-free mass, even if an upward trend in handgrip strength was observed [239]. Therefore, further data are needed to recommend HMB supplementation in LC.

Carnitine is a biofactor involved in fatty acid and energy metabolism, whose deficiency is frequently observed in patients with LC, especially in those with sarcopenia and malnutrition. Therefore, recent research has evaluated the role of L-carnitine supplementation in LC patients. Different studies have reported suppression of skeletal muscle loss [240–242] or increased skeleton [243] in patients with LC. This effect has been related to improving

hyperammonemia [243]; yet, in other research, loss of skeletal muscle was significantly suppressed, even in patients receiving L-carnitine but not showing ammonia decrease [241]. In a study enrolling 18 patients with LC, L-carnitine supplementation (1000 mg/day) associated with BCAAs and additional exercise for six months did not improve HGS but reduced the frequency of complaints of muscle cramping [244]. Different dosages of L-carnitine have been used, ranging from 1000 to 4000 mg/day [240–244], with treatment durations from 3 to 12 months [240–244]. Hence, even if L-carnitine has a potential therapeutic role in sarcopenia in LC, more research is needed to determine whether adding carnitine to a dietary intervention, including BCAAs, is necessary and at what dosage.

Low vitamin D levels have been reported [245,246] and identified as an independent factor for sarcopenia in patients with CLD [247,248]. Therefore, a randomised controlled study enrolling 33 patients with decompensated LC has explored its role as a therapeutic option for sarcopenia. Those who received oral native vitamin D3 at a dose of 2000 IU once a day for 12 months had a significantly greater increase in SMI (median change rate +5.8%) and grip at 12 months ( $p = 2.57 \times 10^{-3}$  and  $9.07 \times 10^{-3}$ ), with a significant decrease in the prevalence of sarcopenia from 80.0% (12/15) to 33.3% (5/15;  $p = 2.53 \times 10^{-2}$ ) [249]. These results need to be confirmed by further studies.

#### 3.4.4. Pharmacotherapy

Since testosterone treatment in older adults was associated with increased muscle mass [250] and improved physical performance [251,252], this hormonal therapy has been evaluated to treat sarcopenia in LC patients. In a 12-month, double-blinded, placebo-controlled trial including 101 men with LC, intramuscular testosterone led to higher appendicular and total lean mass and reduced fat mass without an increase in adverse events [253]. The beneficial role of this treatment has to be assessed in larger cohorts of patients before entering clinical practice.

Metformin is an insulin sensitiser drug widely used for treating type 2 diabetes; it is safe for the liver but not specifically recommended to treat NAFLD [254,255]. Currently, it is being investigated as a potential anti-sarcopenic agent. In fact, it has an inhibiting effect on NF-kappaB-mediated inflammation and oxidation response; it can mimic exercise-activated activated protein kinase (AMPK) signalling, which stimulates muscle anabolism. However, this latter represents a dose–response phenomenon, characterised by low-dose stimulation and high-dose inhibition of AMPK signalling, which raises concerns about a possible untoward effect opposite to the expected one [256]. There are not enough data to establish a favourable, neutral or unfavourable clinical effect of this drug on sarcopenia.

Several novel drugs are currently being investigated for sarcopenia treatment, targeting multiple pathways, such as myostatin, the renin-angiotensin system, androgen receptors, activated protein kinase and ghrelin [256]. However, no published data on these drug trials on liver disease-associated sarcopenia are available. Table 2 summarizes the available evidence on supplementation and pharmacotherapy in the prevention and treatment of sarcopenia in CLD.



**Table 2.** Supplementations and drugs for prevention and treatment of sarcopenia in LC patients.

Molecule	Mechanism	Clinical Effects	Type of Evidence	Limitations
BCAAs	Increased myofibrillar protein synthesis through the mTOR pathway	Significant increase in SMI and MAMC Insignificant increase in HGS	Meta-analysis, including 11 studies	High heterogeneity in dosage (6 to 110 g/day) and supplementation duration (3 to 12 months) Timing of supplementation and combination with resistance training to be defined
HMB	Stimulation of protein synthesis	Conflicting results: significant increase in muscle function and quadriceps muscle mass vs. absence of change in FFM with an upward trend in HGS	Small RCTs	Larger studies are needed to assess efficacy
L-carnitine	Involved in fatty acid and energy metabolism	Suppression of skeletal muscle loss	A few RCTs and retrospective studies	Heterogeneity of dosages (from 1000 to 4000 mg/day) and treatment durations (from 3 to 12 months)
Vitamin-D	Acts through vitamin D receptor in muscles, but detailed mechanisms are still unclear	Increase in SMI	A small RCT	More studies needed to confirm the beneficial effect
Testosterone	Stimulates muscle protein synthesis	Higher appendicular and total lean mass and reduced fat mass	An RCT	Assessment in larger cohorts needed
Metformin	It can mimic exercise-activated activated protein kinase (AMPK) signalling, which stimulates muscle anabolism	NA	NA	Clinical effect on sarcopenia needs to be evaluated

BCAAs, branched-chain amino acids; FFM, fat-free mass; HMB, beta-hydroxy-beta-methyl butyrate; HGS, handgrip strength; MAMC, mid-arm muscle circumference; NA, not available; RCTs, randomised controlled trials; SMI, skeletal muscle index.

#### 4. Bone Density Defects

##### 4.1. Osteoporosis and Bone Density Impairment in NAFLD

Osteoporosis (porous bone) is a disease characterised by bone weakness and an increased risk of fragility fractures that can occur as a result of low-level trauma. A fragile bone can be easily damaged by impact or stress that would not hurt a bone with a normal mineral density [257]. Bone's ability to withstand trauma is the result of a combination of quality elements (structure, micro-architecture and mineral composition of the bone tissue) and quantitative factors (i.e., bone mineral density (BMD)) [258]. BMD is a measurable parameter consisting of the amount of bone mass per unit area or unit volume [259]. It is crucial for diagnosing bone impairment and provides prognostic information for assessing fracture risk.

Osteoporosis is more common among the elderly population because the bones become more porous and weak with age; osteoporosis is also more frequent among women than men because of the reduction in circulating oestrogens following menopause [260]; the morbidity of osteoporosis comes from the associated fractures that significantly impact overall survival [260].

Moreover, even though it appears as a steady element, bone is an active tissue with a high turnover rate: tissue is incessantly resorbed by osteoclasts and rebuilt by

osteoblasts [261]. This process is controlled by local signals (such as growth factors and cytokines) and systemic signals (parathyroid hormone, calcitonin and oestrogen), which cooperate to maintain bone homeostasis [262]. In the elderly, the unbalance between bone formation by osteoblasts and bone resorption by osteoclasts is crucial in the pathogenesis of bone density defects.

Considering the role of the liver in bone metabolism, especially in the vitamin D pathway, the link between NAFLD and bone defects is not surprising [263]. Vitamin D is a fat-soluble vitamin involved in calcium/phosphorus metabolism and bone homeostasis. The main form of vitamin D is vitamin D3 (cholecalciferol) which originates from 7-dehydrocholesterol after ultraviolet (Uv) light irradiation. Vitamin D's principal circulating and storing metabolite is 25-hydroxyvitamin D [25(OH)d], produced in the liver after the 25-hydroxylation of Vitamin D by 25-hydroxylase. Subsequently, 25(OH)d is converted to 1.25(OH)<sub>2</sub>D in the kidney by 1 $\alpha$ -hydroxylase. The biological actions of vitamin D are performed after the binding of 1.25(OH)<sub>2</sub>D to its receptor. When its ligand binds it, it directly or indirectly leads to the expression of various genes, which impact cell differentiation, proliferation, apoptosis, angiogenesis and immunomodulation. In addition, low serum 25(OH)d levels have been reported to be connected to components of the metabolic syndrome [264]. Significant evidence suggests an association between low serum 25(OH)<sub>2</sub>D and NAFLD [265]; hypovitaminosis D is firmly and independently related to NAFLD in the normal adult population without altered liver enzymes [266].

#### 4.2. Prevalence of Bone Density Defects in NAFLD, Cirrhotic NASH and Prognosis Implication

Multiple cross-sectional studies have attempted to clarify the association between NAFLD and bone density defects [267]. Understandably, many conflicting data have been published because of various confounding factors, such as age, sex, race, and nutritional and menstrual conditions, which could influence bone metabolism.

A few studies have ascertained a notable link between lower BMD or higher prevalence of fragility fractures in adolescents and adults and NAFLD [268,269]; however, some studies identified no relevant associations between the two conditions [270,271]. Furthermore, it has also been noticed that there is no association between NAFLD and reduced BMD [272,273], which may suggest that NAFLD (especially NASH) could worsen insulin resistance and determine the release of several pro-inflammatory cytokines and bone-affecting molecules with the development of osteoporosis [274].

In a recent study, Pan et al. evaluated the association between the prevalence and risk of osteoporosis or osteoporotic fracture with NAFLD. The results showed that the prevalence of osteoporosis was higher in male and female NAFLD groups than in the non-NAFLD group, and the risk of osteoporosis or fragility fractures was higher in the fatty liver disease group than in the non-NAFLD group. Finally, data indicated that the risk of osteoporosis or osteoporotic fractures was higher in the male NAFLD group than in the non-NAFLD group, without significant differences among women [274]. Moreover, evidence suggests an increased fracture risk in individuals affected by NAFLD with liver fibrosis compared to NAFLD controls without fibrosis. This could be explained by the reduced liver synthesis of insulin-like growth factor-1 (IGF-1), which stimulates osteoblast proliferation and differentiation resulting in a lower bone turnover [275]. In addition, the surplus of lipid accumulation in the liver determines low-grade, chronic inflammation, which is combined with the development of bone loss, osteoporosis and a higher risk of osteoporotic fractures; accordingly, pro-inflammatory cytokines have an osteoclastogenic activity [276]. For instance, TNF- $\alpha$  can decrease trabecular and cortical bone formation by inhibiting osteoblast differentiation and encouraging osteoblast apoptosis. This cytokine can also promote trabecular and cortical bone resorption by determining the expression of the receptor activator of the nuclear factor kappa-B ligand (RANKL), which prevents osteoclast activation and osteoblast apoptosis [277].

Zhai et al. evaluated the clinical implications of bone impairment in 13,837 adults with NAFLD in the United States, resulting, after adjustment for potential confounding

factors, in an increase in the prevalence of osteopenia/osteoporosis in the femoral neck in adults aged  $\geq 40$  years throughout 2005–2014; furthermore, NAFLD complicated with fibrosis was positively associated with the occurrence of spine fracture [278]. Moreover, hip fractures are firmly associated with reduced BMD at the femoral neck. Hip fractures, which present with pain and an inability to bear weight, almost always demand surgical correction and are combined with a greater reduction in functional status and quality of life than all other types of fracture, with a high risk for short-term mortality [262]. Despite no studies having assessed the relationship between osteoporosis or fragility fractures and survival in patients with NAFLD (or other chronic liver diseases), it is possible to extrapolate some evidence from studies conducted in the general population. Using the DALY (“disability-adjusted life year”) as a measure of burden disease, according to the WHO’s standards, it has been evaluated that fragility fractures are the fourth most severe illness, preceded only by ischemic heart disease, dementia and lung cancer [260]. It is reasonable to assume that fragility fractures should represent a major issue in patients with chronic liver disease, considering their remarkable clinical frailty, and they probably could be a negative prognostic factor in terms of quality of life and survival.

#### 4.3. Diagnosis and Clinical Assessment of Bone Density Defects in NAFLD

The parameter used to identify bone defects is the BMD measure, detected with dual-energy X-ray absorptiometry (DXA). BMD values are standard deviations from the young population’s mean values for the diagnosis. This parameter is called the T-score, and the measurement of the T-score can lead to the diagnosis of osteoporosis (T score  $\leq -2.5$ ) or osteopenia ( $-2.5 < \text{T-score} \leq -1.0$ ) [261].

The bone density of the entire skeleton can be examined, but the most commonly evaluated points are the hip (femoral neck), lumbar region (L1–L4) and wrist. The lifetime risk for femoral, vertebral and wrist fractures is around 40%, similar to cardiovascular disease [257]. Evidence indicated that fragility fractures of osteoporosis were 2.5-fold more common in subjects with NAFLD [279,280]; furthermore, low BMD was more relevant in patients with progressive liver disease, including NASH, and significant fibrosis [279,281]. Intriguingly, Ahn et al. reported that fatty liver index (FLI), a composed formula used to predict the presence of NAFLD (BMI, waist circumference, GGT and triglycerides), was negatively associated with BMD (evaluated with DXA) at all skeletal sites only in men [282]. The link between FLI, BMD and the risk of osteopenia and osteoporosis was independent of insulin resistance [282]. Moreover, diagnosing, monitoring and eventually supplementing with vitamin D and calcium is mandatory in patients with osteopenia or osteoporosis for the known positive effects on bone metabolism [283].

#### 4.4. Prevention and Treatment of Bone Defects in NAFLD/Cirrhotic-NASH Patients

Lifestyle modification is crucial in preventing and treating NAFLD [284]; weight loss is connected with reducing liver fat accumulation and levels of aminotransferase [285]. The extent of weight loss is a determinant of histological improvements in NAFLD and NASH. Although small reductions (3–5% body weight loss) can improve hepatic steatosis and the associated metabolic indicators, superior weight loss (at least 7%) is necessary to improve or resolve NASH [286,287].

Following a Mediterranean diet, with lower calories than required daily, is associated with reduced body weight, hepatic lipid accumulation and insulin resistance [288].

Nevertheless, physical exercise in NAFLD and chronic liver disease is suggested to improve liver disease and maintain and improve BMD and skeletal muscle [289] since physical stress positively impacts bone formation [290]. A previous study evidenced the positive effect of weight-bearing aerobic exercise and resistance training on BMD, and exercise could reduce the risk of falling and fractures in patients affected by osteoporosis [290].

Fragility fractures of osteoporosis can be prevented and treated with several medications, which can be divided into two main categories of drugs: anti-resorptives (mainly bisphosphonates and denosumab) and anabolics (teriparatide and abaloparatide) [262].

Bisphosphonates (BPs) are the most widely used drugs to prevent and treat osteoporosis and osteoporotic fractures. Their ability to be incorporated into the bone matrix, related to their structural analogy to inorganic pyrophosphate, accounts for their high specificity of action expressed only at the bone level, thus reducing pharmacological interactions with other medications and possible side effects [291].

Unfortunately, there have been no large clinical trials specially carried out to assess bisphosphonates' impact on bone impairment in NAFLD/NASH/CLD, but there are a few trials that have been conducted to evaluate the possible efficacy of BPs in patients with primary biliary cholangitis and secondary osteoporosis. Just one RCT performed to compare BPs and a placebo demonstrated improvement in spine and femoral BMD [292]. In 2005, Zein et al. compared the oral administration of alendronate with a placebo in a group of 34 participants with PBC. After one year, a statistically significant improvement in lumbar spine BMD and proximal femur BMD from the baseline was observed in the alendronate group compared to the placebo group, while no difference was observed in the number of vertebral and non-vertebral fractures [293]. Other studies have been performed to compare the use of different BPs in bone loss following PBC [294,295], but not one has shown any effect in reducing the risk of fracture [292]. A lack of evidence may be found in an Indian study, which evaluated the impact of BP administration on a group of cirrhotic patients (notice that cholestatic liver disease was an exclusion criterion) [296]. Bansal et al. orally administered ibandronic acid to cirrhotic patients with osteoporosis, and after six months of follow-up they reported a significant improvement in lumbar and femoral BMD. No effect on fractures has been observed. This study provides low-quality evidence, considering that only 40% of patients completed the trial and were followed up for six months.

The main concern about the oral administration of bisphosphonates in patients with liver disease is the risk of gastro-oesophageal erosion, especially in patients with varices [297]. Although this issue could be avoided through the intravenous administration of bisphosphonates, in none of the analysed studies have serious adverse events been reported [292–296]. Two non-randomised controlled trials have been performed to evaluate the safety of risedronate oral administration in patients with liver cirrhosis and oesophageal varices [298,299]. These studies confirm the effectiveness of BPs in increasing bone mass, especially at the lumbar level. In fact, after one year of treatment, the intervention group showed a significant improvement in lumbar BMD compared to the control group. This improvement was even higher after two years, showing that BMD continued to increase. No improvement in femoral BMD has been noticed. Despite the drug's increased risk of oesophagitis, no gastrointestinal bleeding occurred. It must be noticed that the studies enrolled only patients with low-risk varices, while patients with high-risk bleeding varices underwent pre-intervention EVBL. This point prevents a generalisation about BP administration in cirrhotic patients. Still, it suggests that these medications can be used safely in patients with a low risk of bleeding varices. In contrast, greater caution is required in patients with a higher risk of bleeding.

Denosumab is a human monoclonal IgG2 antibody capable of linking with high affinity to RANKL, a key cytokine in stimulating bone resorption. It inhibits osteoclast activation and function by preventing its interaction with the RANK receptor, expressed on the osteoclast's surface [300]. Compared to bisphosphonates in common clinical practice, denosumab has some main advantages: (1) it leads to a greater improvement in all-site-BMD than BP [301]; (2) denosumab involves a semestral parenteral administration (subcutaneous injection), and it should provide better patient adherence instead of the weekly oral administration of BP; (3) no studies have been performed to assess the safety of BP administration in patients with severe renal impairment, so BP use is contraindicated in subjects with eGFR < 30 mL/min, as opposed to denosumab. Only a retrospective study observed denosumab administration in chronic liver disease patients. It showed a significant improvement in all BMD values and no reported fractures or mild/severe adverse events [302]. This study has many limitations: first of all, it involved only 60 patients with a very short follow-up of

just one year. Despite these limits, it provides evidence of denosumab's effectiveness in reducing bone loss in chronic liver disease patients.

Partial evidence reported that RANKL upregulation could play a key role in NAFLD pathogenesis and be the possible link between hepatic and bone impairment, so its down-regulation could be protective for liver health (and bone, too) [303,304]. A suggestive paper reported amelioration of liver function in a woman with NASH and osteoporosis after denosumab administration [305].

While anti-resorptive drugs improve bone mineral density inhibiting osteoclast activity and preventing loss of bone tissue, anabolic medications stimulate the production of new bone tissue. The main example of this class is teriparatide, an analogue of the human parathyroid hormone (1–34). Despite its effectiveness in gaining bone mass and consequently improving BMD, especially at the spine, this medication cannot be administered for long periods because an increased incidence of osteosarcoma in murine models treated with high doses of teriparatide has been noticed [306]. For this reason, many regulatory agencies have established a maximum treatment period with teriparatide for up to two years. The other limit of anabolic therapies is that their effect on BMD is transient, so at the end of treatment, a switch to anti-resorptive medications is needed to avoid a rebound of bone tissue loss. There are no studies assessing the safety and efficacy of anabolic medications in patients with NAFLD/CLD/ESLD and osteoporosis, but they are probably not suitable for this type of patient, especially regarding the cancer risk.


Despite the high prevalence of NAFLD, no efficacious drugs are currently approved for treating the disease; among the drugs proposed, pioglitazone is used off-label in selected patients affected by NASH with fibrosis stage  $\geq 2$  and type 2 diabetes [307,308]. However, pioglitazone appears to be linked to an increased risk of osteoporotic fractures [309,310]. Since NAFLD and osteoporosis share some molecular and biological pathways, employing drugs that improve both conditions may be important. Recently, GLP1-RAs (mainly Semaglutide and Liraglutide), a class of anti-diabetic and anti-obesity drugs, have provided intriguing data, showing a reduction in liver steatosis and inflammation [311,312], and, at the same time, they appear to have an impact on bone metabolism [310], with favourable effects on bone mineral density [313] and reduction in the risk of fractures [314].

## 5. Conclusions

Patients with poor bone mineral density and sarcopenia are referred to as having osteosarcopenia. Due to the additional negative health consequences that the two diseases predispose towards, those with chronic liver disease and osteosarcopenia are at an increased risk (Figure 1). Osteosarcopenia consequences have a large cost impact on health systems because they are linked to considerable increases in morbidity and mortality.

Early detection of the condition, either by screening people at higher risk, as seen above, or by evaluating patients for clinical characteristics of osteosarcopenia, may assist in avoiding negative effects. Patients with chronic dysmetabolic liver disease may undergo a significant decrease in falls, fractures and functional impairment when following straight-forward therapies, such as resistance exercise, appropriate dietary protein and calcium consumption, and maintenance of normal vitamin D levels.





**Figure 1.** Pathophysiological mechanism and the association between osteoporosis and sarcopenia in non-alcoholic fatty liver disease.

**Author Contributions:** A.C., A.M., F.P. and F.R. conceived and designed the research; B.S., E.D. and L.L. reviewed the literature; A.M., F.P. and F.R. drafted the manuscript; M.L.P. and R.M. designed the tables and figure; A.C. and F.R. edited and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. *Age Ageing* **2019**, *48*, 16–31. [[CrossRef](#)]
2. Malmstrom, T.K.; Miller, D.K.; Simonsick, E.M.; Ferrucci, L.; Morley, J.E. SARC-F: A Symptom Score to Predict Persons with Sarcopenia at Risk for Poor Functional Outcomes. *J. Cachexia Sarcopenia Muscle* **2016**, *7*, 28–36. [[CrossRef](#)] [[PubMed](#)]
3. Mourtzakis, M.; Prado, C.M.M.; Lieffers, J.R.; Reiman, T.; McCargar, L.J.; Baracos, V.E. A Practical and Precise Approach to Quantification of Body Composition in Cancer Patients Using Computed Tomography Images Acquired during Routine Care. *Appl. Physiol. Nutr. Metab.* **2008**, *33*, 997–1006. [[CrossRef](#)] [[PubMed](#)]
4. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and Classification of Cancer Cachexia: An International Consensus. *Lancet. Oncol.* **2011**, *12*, 489–495. [[CrossRef](#)] [[PubMed](#)]
5. Lukaski, H.C.; Kyle, U.G.; Kondrup, J. Assessment of Adult Malnutrition and Prognosis with Bioelectrical Impedance Analysis: Phase Angle and Impedance Ratio. *Curr. Opin. Clin. Nutr. Metab. Care* **2017**, *20*, 330–339. [[CrossRef](#)]

6. Bilborough, J.C.; Greenway, K.; Opar, D.; Livingstone, S.; Cordy, J.; Coutts, A.J. The Accuracy and Precision of DXA for Assessing Body Composition in Team Sport Athletes. *J. Sport. Sci.* **2014**, *32*, 1821–1828. [[CrossRef](#)]
7. Martin, L.; Birdsell, L.; Macdonald, N.; Reiman, T.; Clandinin, M.T.; McCargar, L.J.; Murphy, R.; Ghosh, S.; Sawyer, M.B.; Baracos, V.E. Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **2013**, *31*, 1539–1547. [[CrossRef](#)]
8. Carey, E.J.; Lai, J.C.; Wang, C.W.; Dasarathy, S.; Lobach, I.; Montano-Loza, A.J.; Dunn, M.A. A Multicenter Study to Define Sarcopenia in Patients with End-Stage Liver Disease. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2017**, *23*, 625–633. [[CrossRef](#)]
9. Donini, L.M.; Busetto, L.; Bischoff, S.C.; Cederholm, T.; Ballesteros-Pomar, M.D.; Batsis, J.A.; Bauer, J.M.; Boirie, Y.; Cruz-Jentoft, A.J.; Dicker, D.; et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. *Obes. Facts* **2022**, *15*, 321–335. [[CrossRef](#)]
10. Dodds, R.M.; Syddall, H.E.; Cooper, R.; Benzeval, M.; Deary, I.J.; Dennison, E.M.; Der, G.; Gale, C.R.; Inskip, H.M.; Jagger, C.; et al. Grip Strength across the Life Course: Normative Data from Twelve British Studies. *PLoS ONE* **2014**, *9*, e113637. [[CrossRef](#)]
11. Chen, L.-K.; Woo, J.; Assantachai, P.; Auyeung, T.-W.; Chou, M.-Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J. Am. Med. Dir. Assoc.* **2020**, *21*, 300–307.e2. [[CrossRef](#)]
12. Gallagher, D.; Heymsfield, S.B.; Heo, M.; Jebb, S.A.; Murgatroyd, P.R.; Sakamoto, Y. Healthy Percentage Body Fat Ranges: An Approach for Developing Guidelines Based on Body Mass Index. *Am. J. Clin. Nutr.* **2000**, *72*, 694–701. [[CrossRef](#)]
13. Janssen, I.; Heymsfield, S.B.; Ross, R. Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability. *J. Am. Geriatr. Soc.* **2002**, *50*, 889–896. [[CrossRef](#)] [[PubMed](#)]
14. Batsis, J.A.; Barre, L.K.; Mackenzie, T.A.; Pratt, S.I.; Lopez-Jimenez, F.; Bartels, S.J. Variation in the Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults Associated with Different Research Definitions: Dual-Energy X-Ray Absorptiometry Data from the National Health and Nutrition Examination Survey 1999–2004. *J. Am. Geriatr. Soc.* **2013**, *61*, 974–980. [[CrossRef](#)] [[PubMed](#)]
15. Hausman, G.J.; Basu, U.; Du, M.; Fernyhough-Culver, M.; Dodson, M.V. Intermuscular and Intramuscular Adipose Tissues: Bad vs. Good Adipose Tissues. *Adipocyte* **2014**, *3*, 242–255. [[CrossRef](#)] [[PubMed](#)]
16. Tanaka, M.; Okada, H.; Hashimoto, Y.; Kumagai, M.; Nishimura, H.; Oda, Y.; Fukui, M. Relationship between Nonalcoholic Fatty Liver Disease and Muscle Quality as Well as Quantity Evaluated by Computed Tomography. *Liver Int. Off. J. Int. Assoc. Study Liver* **2020**, *40*, 120–130. [[CrossRef](#)]
17. Kitajima, Y.; Hyogo, H.; Sumida, Y.; Eguchi, Y.; Ono, N.; Kuwashiro, T.; Tanaka, K.; Takahashi, H.; Mizuta, T.; Ozaki, I.; et al. Severity of Non-Alcoholic Steatohepatitis Is Associated with Substitution of Adipose Tissue in Skeletal Muscle. *J. Gastroenterol. Hepatol.* **2013**, *28*, 1507–1514. [[CrossRef](#)]
18. Nachit, M.; Lanthier, N.; Rodriguez, J.; Neyrinck, A.M.; Cani, P.D.; Bindels, L.B.; Hiel, S.; Pachikian, B.D.; Trefois, P.; Thissen, J.-P.; et al. A Dynamic Association between Myosteatosis and Liver Stiffness: Results from a Prospective Interventional Study in Obese Patients. *JHEP Rep. Innov. Hepatol.* **2021**, *3*, 100323. [[CrossRef](#)]
19. Hsieh, Y.-C.; Joo, S.K.; Koo, B.K.; Lin, H.-C.; Lee, D.H.; Chang, M.S.; Park, J.H.; So, Y.H.; Kim, W. Myosteatosis, but Not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2022**, *21*, 388–397.e10. [[CrossRef](#)]
20. Bhanji, R.A.; Moctezuma-Velazquez, C.; Duarte-Rojo, A.; Ebadi, M.; Ghosh, S.; Rose, C.; Montano-Loza, A.J. Myosteatosis and Sarcopenia Are Associated with Hepatic Encephalopathy in Patients with Cirrhosis. *Hepatol. Int.* **2018**, *12*, 377–386. [[CrossRef](#)]
21. Bhanji, R.A.; Narayanan, P.; Moynagh, M.R.; Takahashi, N.; Angirekula, M.; Kennedy, C.C.; Mara, K.C.; Dierkhsing, R.A.; Watt, K.D. Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2019**, *25*, 14–24. [[CrossRef](#)]
22. Montano-Loza, A.J.; Angulo, P.; Meza-Junco, J.; Prado, C.M.M.; Sawyer, M.B.; Beaumont, C.; Esfandiari, N.; Ma, M.; Baracos, V.E. Sarcopenic Obesity and Myosteatosis Are Associated with Higher Mortality in Patients with Cirrhosis. *J. Cachexia Sarcopenia Muscle* **2016**, *7*, 126–135. [[CrossRef](#)] [[PubMed](#)]
23. Koo, B.K.; Kim, D.; Joo, S.K.; Kim, J.H.; Chang, M.S.; Kim, B.G.; Lee, K.L.; Kim, W. Sarcopenia Is an Independent Risk Factor for Non-Alcoholic Steatohepatitis and Significant Fibrosis. *J. Hepatol.* **2017**, *66*, 123–131. [[CrossRef](#)] [[PubMed](#)]
24. Hong, J.; Shin, W.-K.; Lee, J.W.; Kim, Y. Relationship Between Protein Intake and Sarcopenia in the Elderly with Nonalcoholic Fatty Liver Disease Based on the Fourth and Fifth Korea National Health and Nutrition Examination Survey. *Metab. Syndr. Relat. Disord.* **2021**, *19*, 452–459. [[CrossRef](#)] [[PubMed](#)]
25. Golabi, P.; Gerber, L.; Paik, J.M.; Deshpande, R.; de Avila, L.; Younossi, Z.M. Contribution of Sarcopenia and Physical Inactivity to Mortality in People with Non-Alcoholic Fatty Liver Disease. *JHEP Rep. Innov. Hepatol.* **2020**, *2*, 100171. [[CrossRef](#)]
26. Wang, Y.-M.; Zhu, K.-F.; Zhou, W.-J.; Zhang, Q.; Deng, D.-F.; Yang, Y.-C.; Lu, W.-W.; Xu, J.; Yang, Y.-M. Sarcopenia Is Associated with the Presence of Nonalcoholic Fatty Liver Disease in Zhejiang Province, China: A Cross-Sectional Observational Study. *BMC Geriatr.* **2021**, *21*, 55. [[CrossRef](#)]
27. Linge, J.; Ekstedt, M.; Dahlqvist Leinhard, O. Adverse Muscle Composition Is Linked to Poor Functional Performance and Metabolic Comorbidities in NAFLD. *JHEP Rep. Innov. Hepatol.* **2021**, *3*, 100197. [[CrossRef](#)]

28. Petta, S.; Ciminnisi, S.; Di Marco, V.; Cabibi, D.; Cammà, C.; Licata, A.; Marchesini, G.; Craxi, A. Sarcopenia Is Associated with Severe Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *Aliment. Pharmacol. Ther.* **2017**, *45*, 510–518. [[CrossRef](#)]
29. Lee, Y.; Kim, S.U.; Song, K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Lee, B.-W.; Kang, E.S.; Cha, B.-S.; Han, K.-H. Sarcopenia Is Associated with Significant Liver Fibrosis Independently of Obesity and Insulin Resistance in Nonalcoholic Fatty Liver Disease: Nationwide Surveys (KNHANES 2008–2011). *Hepatology* **2016**, *63*, 776–786. [[CrossRef](#)]
30. Almeida, N.S.; Rocha, R.; de Souza, C.A.; da Cruz, A.C.S.; Ribeiro, B.D.R.; Vieira, L.V.; Daltro, C.; Silva, R.; Sarno, M.; Cotrim, H.P. Prevalence of Sarcopenia Using Different Methods in Patients with Non-Alcoholic Fatty Liver Disease. *World J. Hepatol.* **2022**, *14*, 1643–1651. [[CrossRef](#)]
31. Alferink, L.J.M.; Trajanoska, K.; Erler, N.S.; Schoufour, J.D.; de Knecht, R.J.; Ikram, M.A.; Janssen, H.L.A.; Franco, O.H.; Metselaar, H.J.; Rivadeneira, F.; et al. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. *J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.* **2019**, *34*, 1254–1263. [[CrossRef](#)]
32. Cai, C.; Song, X.; Chen, Y.; Yu, C. Relationship between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Hepatol. Int.* **2020**, *14*, 115–126. [[CrossRef](#)] [[PubMed](#)]
33. Kim, G.; Lee, S.-E.; Lee, Y.-B.; Jun, J.E.; Ahn, J.; Bae, J.C.; Jin, S.-M.; Hur, K.Y.; Jee, J.H.; Lee, M.-K.; et al. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. *Hepatology* **2018**, *68*, 1755–1768. [[CrossRef](#)] [[PubMed](#)]
34. Lee, M.J.; Kim, E.-H.; Bae, S.-J.; Kim, G.-A.; Park, S.W.; Choe, J.; Jung, C.H.; Lee, W.J.; Kim, H.-K. Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study. *Gut Liver* **2019**, *13*, 67–76. [[CrossRef](#)] [[PubMed](#)]
35. Chung, G.E.; Kim, M.J.; Yim, J.Y.; Kim, J.S.; Yoon, J.W. Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease. *J. Obes. Metab. Syndr.* **2019**, *28*, 129–138. [[CrossRef](#)]
36. Wijarnpreecha, K.; Kim, D.; Raymond, P.; Scribani, M.; Ahmed, A. Associations between Sarcopenia and Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in the USA. *Eur. J. Gastroenterol. Hepatol.* **2019**, *31*, 1121–1128. [[CrossRef](#)] [[PubMed](#)]
37. Zhang, Y.; Lu, D.; Wang, R.; Fu, W.; Zhang, S. Relationship between Muscle Mass/Strength and Hepatic Fat Content in Post-Menopausal Women. *Medicina* **2019**, *55*, 629. [[CrossRef](#)]
38. Kim, H.Y.; Kim, C.W.; Park, C.-H.; Choi, J.Y.; Han, K.; Merchant, A.T.; Park, Y.-M. Low Skeletal Muscle Mass Is Associated with Non-Alcoholic Fatty Liver Disease in Korean Adults: The Fifth Korea National Health and Nutrition Examination Survey. *Hepatobiliary Pancreat. Dis. Int. HBPDI* **2016**, *15*, 39–47. [[CrossRef](#)]
39. Gan, D.; Wang, L.; Jia, M.; Ru, Y.; Ma, Y.; Zheng, W.; Zhao, X.; Yang, F.; Wang, T.; Mu, Y.; et al. Low Muscle Mass and Low Muscle Strength Associate with Nonalcoholic Fatty Liver Disease. *Clin. Nutr.* **2020**, *39*, 1124–1130. [[CrossRef](#)]
40. Hong, K.S.; Kim, M.C.; Ahn, J.H. Sarcopenia Is an Independent Risk Factor for NAFLD in COPD: A Nationwide Survey (KNHANES 2008–2011). *Int. J. Chronic Obstr. Pulm. Dis.* **2020**, *15*, 1005–1014. [[CrossRef](#)]
41. Kang, M.K.; Kim, K.O.; Kim, M.C.; Park, J.G.; Jang, B.I. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease. *Dig. Dis.* **2020**, *38*, 507–514. [[CrossRef](#)] [[PubMed](#)]
42. Seo, D.H.; Lee, Y.-H.; Park, S.W.; Choi, Y.J.; Huh, B.W.; Lee, E.; Huh, K.B.; Kim, S.H.; Cha, B.-S. Sarcopenia Is Associated with Non-Alcoholic Fatty Liver Disease in Men with Type 2 Diabetes. *Diabetes Metab.* **2020**, *46*, 362–369. [[CrossRef](#)] [[PubMed](#)]
43. Pasco, J.A.; Sui, S.X.; West, E.C.; Anderson, K.B.; Rufus-Membere, P.; Tembo, M.C.; Hyde, N.K.; Williams, L.J.; Liu, Z.S.J.; Kotowicz, M.A. Fatty Liver Index and Skeletal Muscle Density. *Calcif. Tissue Int.* **2022**, *110*, 649–657. [[CrossRef](#)] [[PubMed](#)]
44. Hyun Kim, K.; Kyung Kim, B.; Yong Park, J.; Young Kim, D.; Hoon Ahn, S.; Han, K.-H.; Kim, S.U. Sarcopenia Assessed Using Bioimpedance Analysis Is Associated Independently with Significant Liver Fibrosis in Patients with Chronic Liver Diseases. *Eur. J. Gastroenterol. Hepatol.* **2020**, *32*, 58–65. [[CrossRef](#)]
45. Gao, F.; Zheng, K.I.; Zhu, P.-W.; Li, Y.-Y.; Ma, H.-L.; Li, G.; Tang, L.-J.; Rios, R.S.; Liu, W.-Y.; Pan, X.-Y.; et al. FNDC5 Polymorphism Influences the Association between Sarcopenia and Liver Fibrosis in Adults with Biopsy-Proven Non-Alcoholic Fatty Liver Disease. *Br. J. Nutr.* **2021**, *126*, 813–824. [[CrossRef](#)] [[PubMed](#)]
46. Chun, H.S.; Kim, M.N.; Lee, J.S.; Lee, H.W.; Kim, B.K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Kim, S.U. Risk Stratification Using Sarcopenia Status among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. *J. Cachexia Sarcopenia Muscle* **2021**, *12*, 1168–1178. [[CrossRef](#)]
47. Rigor, J.; Vasconcelos, R.; Lopes, R.; Moreira, T.; Barata, P.; Martins-Mendes, D. Associations between Muscle Mass, Strength, and Performance and Non-Alcoholic Fatty Liver Disease. *Minerva Gastroenterol.* **2022**, *in press*. [[CrossRef](#)] [[PubMed](#)]
48. Hsieh, Y.-C.; Joo, S.K.; Koo, B.K.; Lin, H.-C.; Kim, W. Muscle Alterations Are Independently Associated with Significant Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. *Liver Int. Off. J. Int. Assoc. Study Liver* **2021**, *41*, 494–504. [[CrossRef](#)] [[PubMed](#)]
49. Sung, M.J.; Lim, T.S.; Jeon, M.Y.; Lee, H.W.; Kim, B.K.; Kim, D.Y.; Ahn, S.H.; Han, K.-H.; Park, J.Y.; Kim, S.U. Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. *Gut Liver* **2020**, *14*, 626–635. [[CrossRef](#)]
50. Seko, Y.; Mizuno, N.; Okishio, S.; Takahashi, A.; Kataoka, S.; Okuda, K.; Furuta, M.; Takemura, M.; Taketani, H.; Umemura, A.; et al. Clinical and Pathological Features of Sarcopenia-Related Indices in Patients with Non-Alcoholic Fatty Liver Disease. *Hepatol. Res. Off. J. Jpn. Soc. Hepatol.* **2019**, *49*, 627–636. [[CrossRef](#)]



51. Petermann-Rocha, F.; Gray, S.R.; Forrest, E.; Welsh, P.; Sattar, N.; Celis-Morales, C.; Ho, F.K.; Pell, J.P. Associations of Muscle Mass and Grip Strength with Severe NAFLD: A Prospective Study of 333,295 UK Biobank Participants. *J. Hepatol.* **2022**, *76*, 1021–1029. [[CrossRef](#)]
52. Lee, H.J.; Lee, D.C.; Kim, C.O. Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. *Front. Endocrinol.* **2021**, *12*, 599339. [[CrossRef](#)]
53. Han, E.; Kim, M.K.; Im, S.-S.; Jang, B.K.; Kim, H.S. Non-Alcoholic Fatty Liver Disease and Sarcopenia Is Associated with the Risk of Albuminuria Independent of Insulin Resistance, and Obesity. *J. Diabetes Its Complicat.* **2022**, *36*, 108253. [[CrossRef](#)]
54. Han, E.; Lee, Y.-H.; Kim, Y.D.; Kim, B.K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Lee, B.-W.; Kang, E.S.; Cha, B.-S.; et al. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. *Am. J. Gastroenterol.* **2020**, *115*, 584–595. [[CrossRef](#)]
55. Kouvari, M.; Polyzos, S.A.; Chrysohoou, C.; Skoumas, J.; Pitsavos, C.S.; Panagiotakos, D.B.; Mantzoros, C.S. Skeletal Muscle Mass and Abdominal Obesity Are Independent Predictors of Hepatic Steatosis and Interact to Predict Ten-Year Cardiovascular Disease Incidence: Data from the ATTICA Cohort Study. *Clin. Nutr.* **2022**, *41*, 1281–1289. [[CrossRef](#)]
56. Moon, J.H.; Koo, B.K.; Kim, W. Non-Alcoholic Fatty Liver Disease and Sarcopenia Additively Increase Mortality: A Korean Nationwide Survey. *J. Cachexia Sarcopenia Muscle* **2021**, *12*, 964–972. [[CrossRef](#)] [[PubMed](#)]
57. Sun, X.; Liu, Z.; Chen, F.; Du, T. Sarcopenia Modifies the Associations of Nonalcoholic Fatty Liver Disease with All-Cause and Cardiovascular Mortality among Older Adults. *Sci. Rep.* **2021**, *11*, 15647. [[CrossRef](#)] [[PubMed](#)]
58. Kim, D.; Wijarnpreecha, K.; Sandhu, K.K.; Cholkankaril, G.; Ahmed, A. Sarcopenia in Nonalcoholic Fatty Liver Disease and All-Cause and Cause-Specific Mortality in the United States. *Liver Int. Off. J. Int. Assoc. Study Liver* **2021**, *41*, 1832–1840. [[CrossRef](#)]
59. Nachit, M.; Kwanten, W.J.; Thissen, J.-P.; Op De Beeck, B.; Van Gaal, L.; Vonghia, L.; Verrijken, A.; Driessen, A.; Horsmans, Y.; Francque, S.; et al. Muscle Fat Content Is Strongly Associated with NASH: A Longitudinal Study in Patients with Morbid Obesity. *J. Hepatol.* **2021**, *75*, 292–301. [[CrossRef](#)] [[PubMed](#)]
60. Lee, H.J.; Chang, J.S.; Ahn, J.H.; Kim, M.Y.; Park, K.-S.; Ahn, Y.-S.; Koh, S.B. Association Between Low Muscle Mass and Non-Alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea. *J. Prev. Med. Public Health = Yebang Uihakhoe Chi* **2021**, *54*, 412–421. [[CrossRef](#)] [[PubMed](#)]
61. De Munck, T.J.I.; Verhaegh, P.; Lodewick, T.; Bakers, F.; Jonkers, D.; Masclee, A.A.M.; Verbeek, J.; Koek, G.H. Myosteatorsis in Nonalcoholic Fatty Liver Disease: An Exploratory Study. *Clin. Res. Hepatol. Gastroenterol.* **2021**, *45*, 101500. [[CrossRef](#)] [[PubMed](#)]
62. Debroy, P.; Lake, J.E.; Malagoli, A.; Guaraldi, G. Relationship between Grip Strength and Nonalcoholic Fatty Liver Disease in Men Living with HIV Referred to a Metabolic Clinic. *J. Frailty Aging* **2019**, *8*, 150–153. [[CrossRef](#)] [[PubMed](#)]
63. Kim, B.-J.; Ahn, S.H.; Lee, S.H.; Hong, S.; Hamrick, M.W.; Isales, C.M.; Koh, J.-M. Lower Hand Grip Strength in Older Adults with Non-Alcoholic Fatty Liver Disease: A Nationwide Population-Based Study. *Aging* **2019**, *11*, 4547–4560. [[CrossRef](#)]
64. Cruz, J.F.; Ferrari, Y.A.C.; Machado, C.P.; Santana, N.N.; Mota, A.V.H.; Lima, S.O. Sarcopenia and Severity of Non-Alcoholic Fatty Liver Disease. *Arq. Gastroenterol.* **2019**, *56*, 357–360. [[CrossRef](#)]
65. Kang, S.; Moon, M.K.; Kim, W.; Koo, B.K. Association between Muscle Strength and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease: A Korean Nationwide Survey. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 1232–1241. [[CrossRef](#)]
66. Lee, S.-B.; Kwon, Y.-J.; Jung, D.-H.; Kim, J.-K. Association of Muscle Strength with Non-Alcoholic Fatty Liver Disease in Korean Adults. *Int. J. Environ. Res. Public Health* **2022**, *19*, 1675. [[CrossRef](#)] [[PubMed](#)]
67. Kwon, Y.; Jeong, S.J. Relative Skeletal Muscle Mass Is an Important Factor in Non-Alcoholic Fatty Liver Disease in Non-Obese Children and Adolescents. *J. Clin. Med.* **2020**, *9*, 3355. [[CrossRef](#)]
68. Pacifico, L.; Perla, F.M.; Andreoli, G.; Grieco, R.; Pierimarchi, P.; Chiesa, C. Nonalcoholic Fatty Liver Disease Is Associated with Low Skeletal Muscle Mass in Overweight/Obese Youths. *Front. Pediatr.* **2020**, *8*, 158. [[CrossRef](#)]
69. Yodoshi, T.; Orkin, S.; Romantic, E.; Hitchcock, K.; Clachar, A.-C.A.; Bramlage, K.; Sun, Q.; Fei, L.; Trout, A.T.; Xanthakos, S.A.; et al. Impedance-Based Measures of Muscle Mass Can Be Used to Predict Severity of Hepatic Steatosis in Pediatric Nonalcoholic Fatty Liver Disease. *Nutrition* **2021**, *91–92*, 111447. [[CrossRef](#)]
70. Giusto, M.; Lattanzi, B.; Albanese, C.; Galtieri, A.; Farcomeni, A.; Giannelli, V.; Lucidi, C.; Di Martino, M.; Catalano, C.; Merli, M. Sarcopenia in Liver Cirrhosis: The Role of Computed Tomography Scan for the Assessment of Muscle Mass Compared with Dual-Energy X-Ray Absorptiometry and Anthropometry. *Eur. J. Gastroenterol. Hepatol.* **2015**, *27*, 328–334. [[CrossRef](#)]
71. Hanai, T.; Shiraki, M.; Nishimura, K.; Ohnishi, S.; Imai, K.; Suetsugu, A.; Takai, K.; Shimizu, M.; Moriwaki, H. Sarcopenia Impairs Prognosis of Patients with Liver Cirrhosis. *Nutrition* **2015**, *31*, 193–199. [[CrossRef](#)] [[PubMed](#)]
72. Hanai, T.; Shiraki, M.; Ohnishi, S.; Miyazaki, T.; Ideta, T.; Kochi, T.; Imai, K.; Suetsugu, A.; Takai, K.; Moriwaki, H.; et al. Rapid Skeletal Muscle Wasting Predicts Worse Survival in Patients with Liver Cirrhosis. *Hepatol. Res. Off. J. Jpn. Soc. Hepatol.* **2016**, *46*, 743–751. [[CrossRef](#)] [[PubMed](#)]
73. Montano-Loza, A.J. Severe Muscle Depletion Predicts Postoperative Length of Stay but Is Not Associated with Survival after Liver Transplantation. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2014**, *20*, 1424. [[CrossRef](#)]
74. Alexopoulos, T.; Vasilieva, L.; Kontogianni, M.D.; Tenta, R.; Georgiou, A.; Stroumpouli, E.; Mani, I.; Alexopoulou, A. Myostatin in Combination with Creatine Phosphokinase or Albumin May Differentiate Patients with Cirrhosis and Sarcopenia. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2021**, *321*, G543–G551. [[CrossRef](#)]

75. Zeng, X.; Shi, Z.-W.; Yu, J.-J.; Wang, L.-F.; Luo, Y.-Y.; Jin, S.-M.; Zhang, L.-Y.; Tan, W.; Shi, P.-M.; Yu, H.; et al. Sarcopenia as a Prognostic Predictor of Liver Cirrhosis: A Multicentre Study in China. *J. Cachexia Sarcopenia Muscle* **2021**, *12*, 1948–1958. [[CrossRef](#)]
76. Topan, M.-M.; Sporea, I.; Dănilă, M.; Popescu, A.; Ghiuchici, A.-M.; Lupușoru, R.; Șirli, R. Impact of Sarcopenia on Survival and Clinical Outcomes in Patients with Liver Cirrhosis. *Front. Nutr.* **2021**, *8*, 766451. [[CrossRef](#)]
77. Topan, M.-M.; Sporea, I.; Dănilă, M.; Popescu, A.; Ghiuchici, A.-M.; Lupușoru, R.; Șirli, R. Comparison of Different Nutritional Assessment Tools in Detecting Malnutrition and Sarcopenia among Cirrhotic Patients. *Diagnostics* **2022**, *12*, 893. [[CrossRef](#)]
78. Guo, G.; Li, C.; Hui, Y.; Mao, L.; Sun, M.; Li, Y.; Yang, W.; Wang, X.; Yu, Z.; Fan, X.; et al. Sarcopenia and Frailty Combined Increases the Risk of Mortality in Patients with Decompensated Cirrhosis. *Ther. Adv. Chronic Dis.* **2022**, *13*, 20406223221109652. [[CrossRef](#)]
79. Sugiyama, Y.; Ishizu, Y.; Ando, Y.; Yokoyama, S.; Yamamoto, K.; Ito, T.; Imai, N.; Nakamura, M.; Honda, T.; Kawashima, H.; et al. Obesity and Myosteatosis: The Two Characteristics of Dynapenia in Patients with Cirrhosis. *Eur. J. Gastroenterol. Hepatol.* **2021**, *33*, e916–e921. [[CrossRef](#)]
80. Hernández-Conde, M.; Llop, E.; Gómez-Pimpollo, L.; Blanco, S.; Rodríguez, L.; Fernández Carrillo, C.; Perelló, C.; López-Gómez, M.; Martínez-Porras, J.L.; Fernández-Puga, N.; et al. A Nomogram as an Indirect Method to Identify Sarcopenia in Patients with Liver Cirrhosis. *Ann. Hepatol.* **2022**, *27*, 100723. [[CrossRef](#)]
81. Nakamura, A.; Yoshimura, T.; Sato, T.; Ichikawa, T. Diagnosis and Pathogenesis of Sarcopenia in Chronic Liver Disease Using Liver Magnetic Resonance Imaging. *Cureus* **2022**, *14*, e24676. [[CrossRef](#)] [[PubMed](#)]
82. Tantai, X.; Liu, Y.; Yeo, Y.H.; Praktiknjo, M.; Mauro, E.; Hamaguchi, Y.; Engelmann, C.; Zhang, P.; Jeong, J.Y.; van Vugt, J.L.A.; et al. Effect of Sarcopenia on Survival in Patients with Cirrhosis: A Meta-Analysis. *J. Hepatol.* **2022**, *76*, 588–599. [[CrossRef](#)]
83. van Vugt, J.L.A.; Levolger, S.; de Bruin, R.W.F.; van Rosmalen, J.; Metselaar, H.J.; IJzermans, J.N.M. Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. *Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg.* **2016**, *16*, 2277–2292. [[CrossRef](#)]
84. Kim, G.; Kang, S.H.; Kim, M.Y.; Baik, S.K. Prognostic Value of Sarcopenia in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. *PLoS ONE* **2017**, *12*, e0186990. [[CrossRef](#)]
85. Shanavas, N.; Devadas, K.; Nahaz, N.; Varghese, J.; Cyriac, R.; Mathew, D. Association of Sarcopenia with Health Related Quality of Life in Cirrhotics. *J. Assoc. Physicians India* **2021**, *69*, 11–12. [[PubMed](#)]
86. Ando, Y.; Ishigami, M.; Ito, T.; Ishizu, Y.; Kuzuya, T.; Honda, T.; Ishikawa, T.; Fujishiro, M. Sarcopenia Impairs Health-Related Quality of Life in Cirrhotic Patients. *Eur. J. Gastroenterol. Hepatol.* **2019**, *31*, 1550–1556. [[CrossRef](#)]
87. Ebadi, M.; Bhanji, R.A.; Dunichand-Hoedl, A.R.; Mazurak, V.C.; Baracos, V.E.; Montano-Loza, A.J. Sarcopenia Severity Based on Computed Tomography Image Analysis in Patients with Cirrhosis. *Nutrients* **2020**, *12*, 3463. [[CrossRef](#)] [[PubMed](#)]
88. Badran, H.; Elsabaawy, M.M.; Ragab, A.; Aly, R.A.; Alsebaey, A.; Sabry, A. Baseline Sarcopenia Is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients. *Asian Pac. J. Cancer Prev. APJCP* **2020**, *21*, 3285–3290. [[CrossRef](#)]
89. Dajti, E.; Renzulli, M.; Ravaioli, F.; Marasco, G.; Vara, G.; Brandi, N.; Rossini, B.; Colecchia, L.; Alemanni, L.V.; Ferrarese, A.; et al. The Interplay between Sarcopenia and Portal Hypertension Predicts Ascites and Mortality in Cirrhosis. *Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver*, 2022, in press. [[CrossRef](#)]
90. Dajti, E.; Renzulli, M.; Colecchia, A.; Bacchi-Reggiani, M.L.; Milandri, M.; Rossini, B.; Ravaioli, F.; Marasco, G.; Alemanni, L.V.; Ierardi, A.M.; et al. Size and Location of Spontaneous Portosystemic Shunts Predict the Risk of Decompensation in Cirrhotic Patients. *Dig. Liver Dis.* **2022**, *54*, 103–110. [[CrossRef](#)]
91. Miwa, T.; Hanai, T.; Nishimura, K.; Maeda, T.; Ogiso, Y.; Imai, K.; Suetsugu, A.; Takai, K.; Shiraki, M.; Shimizu, M. Handgrip Strength Stratifies the Risk of Covert and Overt Hepatic Encephalopathy in Patients with Cirrhosis. *JPEN J. Parenter. Enter. Nutr.* **2022**, *46*, 858–866. [[CrossRef](#)] [[PubMed](#)]
92. Faron, A.; Abu-Omar, J.; Chang, J.; Böhling, N.; Sprinkart, A.M.; Attenberger, U.; Rockstroh, J.K.; Luu, A.M.; Jansen, C.; Strassburg, C.P.; et al. Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients. *Front. Med.* **2022**, *9*, 831005. [[CrossRef](#)] [[PubMed](#)]
93. Wijarnpreecha, K.; Werlang, M.; Panjawatnan, P.; Kroner, P.T.; Cheungpasitporn, W.; Lukens, F.J.; Pungpapong, S.; Ungprasert, P. Association between Sarcopenia and Hepatic Encephalopathy: A Systematic Review and Meta-Analysis. *Ann. Hepatol.* **2020**, *19*, 245–250. [[CrossRef](#)] [[PubMed](#)]
94. Nardelli, S.; Lattanzi, B.; Merli, M.; Farcomeni, A.; Gioia, S.; Ridola, L.; Riggio, O. Muscle Alterations Are Associated with Minimal and Overt Hepatic Encephalopathy in Patients with Liver Cirrhosis. *Hepatology* **2019**, *70*, 1704–1713. [[CrossRef](#)] [[PubMed](#)]
95. Gioia, S.; Merli, M.; Nardelli, S.; Lattanzi, B.; Pitocchi, F.; Ridola, L.; Riggio, O. The Modification of Quantity and Quality of Muscle Mass Improves the Cognitive Impairment after TIPS. *Liver Int. Off. J. Int. Assoc. Study Liver* **2019**, *39*, 871–877. [[CrossRef](#)]
96. Chang, K.-V.; Chen, J.-D.; Wu, W.-T.; Huang, K.-C.; Lin, H.-Y.; Han, D.-S. Is Sarcopenia Associated with Hepatic Encephalopathy in Liver Cirrhosis? A Systematic Review and Meta-Analysis. *J. Formos. Med. Assoc. = Taiwan Yi Zhi* **2019**, *118*, 833–842. [[CrossRef](#)]
97. Hanai, T.; Shiraki, M.; Watanabe, S.; Kochi, T.; Imai, K.; Suetsugu, A.; Takai, K.; Moriwaki, H.; Shimizu, M. Sarcopenia Predicts Minimal Hepatic Encephalopathy in Patients with Liver Cirrhosis. *Hepatol. Res. Off. J. Jpn. Soc. Hepatol.* **2017**, *47*, 1359–1367. [[CrossRef](#)]

98. Tateyama, M.; Naoe, H.; Tanaka, M.; Tanaka, K.; Narahara, S.; Tokunaga, T.; Kawasaki, T.; Yoshimaru, Y.; Nagaoka, K.; Watanabe, T.; et al. Loss of Skeletal Muscle Mass Affects the Incidence of Minimal Hepatic Encephalopathy: A Case Control Study. *BMC Gastroenterol.* **2020**, *20*, 371. [[CrossRef](#)]
99. Marasco, G.; Dajti, E.; Ravaioli, F.; Brocchi, S.; Rossini, B.; Alemanni, L.V.; Peta, G.; Bartalena, L.; Golfieri, R.; Festi, D.; et al. Clinical Impact of Sarcopenia Assessment in Patients with Liver Cirrhosis. *Expert Rev. Gastroenterol. Hepatol.* **2021**, *15*, 377–388. [[CrossRef](#)]
100. Feng, Z.; Zhao, H.; Jiang, Y.; He, Z.; Sun, X.; Rong, P.; Wang, W. Sarcopenia Associates with Increased Risk of Hepatocellular Carcinoma among Male Patients with Cirrhosis. *Clin. Nutr.* **2020**, *39*, 3132–3139. [[CrossRef](#)]
101. Marasco, G.; Serenari, M.; Renzulli, M.; Alemanni, L.V.; Rossini, B.; Pettinari, I.; Dajti, E.; Ravaioli, F.; Golfieri, R.; Cescon, M.; et al. Clinical Impact of Sarcopenia Assessment in Patients with Hepatocellular Carcinoma Undergoing Treatments. *J. Gastroenterol.* **2020**, *55*, 927–943. [[CrossRef](#)] [[PubMed](#)]
102. Marasco, G.; Dajti, E.; Serenari, M.; Alemanni, L.V.; Ravaioli, F.; Ravaioli, M.; Vestito, A.; Vara, G.; Festi, D.; Golfieri, R.; et al. Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis. *Cancers* **2022**, *14*, 1935. [[CrossRef](#)]
103. Welch, N.; Attaway, A.; Bellar, A.; Alkhafaji, H.; Vural, A.; Dasarathy, S. Compound Sarcopenia in Hospitalized Patients with Cirrhosis Worsens Outcomes with Increasing Age. *Nutrients* **2021**, *13*, 659. [[CrossRef](#)] [[PubMed](#)]
104. Vural, A.; Attaway, A.; Welch, N.; Zein, J.; Dasarathy, S. Skeletal Muscle Loss Phenotype in Cirrhosis: A Nationwide Analysis of Hospitalized Patients. *Clin. Nutr.* **2020**, *39*, 3711–3720. [[CrossRef](#)] [[PubMed](#)]
105. Anand, A.; Mohta, S.; Agarwal, S.; Sharma, S.; Gopi, S.; Gunjan, D.; Madhusudhan, K.S.; Singh, N.; Saraya, A. European Working Group on Sarcopenia in Older People (EWGSOP2) Criteria with Population-Based Skeletal Muscle Index Best Predicts Mortality in Asians with Cirrhosis. *J. Clin. Exp. Hepatol.* **2022**, *12*, 52–60. [[CrossRef](#)]
106. Durand, F.; Buyse, S.; Francoz, C.; Laouénan, C.; Bruno, O.; Belghiti, J.; Moreau, R.; Vilgrain, V.; Valla, D. Prognostic Value of Muscle Atrophy in Cirrhosis Using Psoas Muscle Thickness on Computed Tomography. *J. Hepatol.* **2014**, *60*, 1151–1157. [[CrossRef](#)]
107. Cho, Y.S.; Lee, H.Y.; Jeong, J.Y.; Lee, J.G.; Kim, T.Y.; Nam, S.W.; Sohn, J.H. Computed Tomography-Determined Body Composition Abnormalities Usefully Predict Long-Term Mortality in Patients with Liver Cirrhosis. *J. Comput. Assist. Tomogr.* **2021**, *45*, 684–690. [[CrossRef](#)]
108. Paternostro, R.; Bardach, C.; Hofer, B.S.; Scheiner, B.; Schwabl, P.; Asenbaum, U.; Ba-Ssalamah, A.; Scharitzer, M.; Bucscis, T.; Simbrunner, B.; et al. Prognostic Impact of Sarcopenia in Cirrhotic Patients Stratified by Different Severity of Portal Hypertension. *Liver Int. Off. J. Int. Assoc. Study Liver* **2021**, *41*, 799–809. [[CrossRef](#)]
109. Beer, L.; Bastati, N.; Ba-Ssalamah, A.; Pötter-Lang, S.; Lampichler, K.; Bican, Y.; Lauber, D.; Hodge, J.; Binter, T.; Pomej, K.; et al. MRI-Defined Sarcopenia Predicts Mortality in Patients with Chronic Liver Disease. *Liver Int. Off. J. Int. Assoc. Study Liver* **2020**, *40*, 2797–2807. [[CrossRef](#)]
110. Paternostro, R.; Lampichler, K.; Bardach, C.; Asenbaum, U.; Landler, C.; Bauer, D.; Mandorfer, M.; Schwarzer, R.; Trauner, M.; Reiberger, T.; et al. The Value of Different CT-Based Methods for Diagnosing Low Muscle Mass and Predicting Mortality in Patients with Cirrhosis. *Liver Int. Off. J. Int. Assoc. Study Liver* **2019**, *39*, 2374–2385. [[CrossRef](#)] [[PubMed](#)]
111. Kim, T.Y.; Kim, M.Y.; Sohn, J.H.; Kim, S.M.; Ryu, J.A.; Lim, S.; Kim, Y. Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites. *J. Korean Med. Sci.* **2014**, *29*, 1253–1259. [[CrossRef](#)]
112. Kikuchi, N.; Uojima, H.; Hidaka, H.; Iwasaki, S.; Wada, N.; Kubota, K.; Nakazawa, T.; Shibuya, A.; Fujikawa, T.; Kako, M.; et al. Prospective Study for an Independent Predictor of Prognosis in Liver Cirrhosis Based on the New Sarcopenia Criteria Produced by the Japan Society of Hepatology. *Hepatol. Res. Off. J. Jpn. Soc. Hepatol.* **2021**, *51*, 968–978. [[CrossRef](#)]
113. Moctezuma-Velazquez, C.; Ebadi, M.; Bhanji, R.A.; Stirnimann, G.; Tandon, P.; Montano-Loza, A.J. Limited Performance of Subjective Global Assessment Compared to Computed Tomography-Determined Sarcopenia in Predicting Adverse Clinical Outcomes in Patients with Cirrhosis. *Clin. Nutr.* **2019**, *38*, 2696–2703. [[CrossRef](#)]
114. Golse, N.; Bucur, P.O.; Ciacio, O.; Pittau, G.; Sa Cunha, A.; Adam, R.; Castaing, D.; Antonini, T.; Coilly, A.; Samuel, D.; et al. A New Definition of Sarcopenia in Patients with Cirrhosis Undergoing Liver Transplantation. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2017**, *23*, 143–154. [[CrossRef](#)]
115. Hara, N.; Iwasa, M.; Sugimoto, R.; Mifuji-Moroka, R.; Yoshikawa, K.; Terasaka, E.; Hattori, A.; Ishidome, M.; Kobayashi, Y.; Hasegawa, H.; et al. Sarcopenia and Sarcopenic Obesity Are Prognostic Factors for Overall Survival in Patients with Cirrhosis. *Intern. Med.* **2016**, *55*, 863–870. [[CrossRef](#)]
116. Kang, S.H.; Jeong, W.K.; Baik, S.K.; Cha, S.H.; Kim, M.Y. Impact of Sarcopenia on Prognostic Value of Cirrhosis: Going beyond the Hepatic Venous Pressure Gradient and MELD Score. *J. Cachexia Sarcopenia Muscle* **2018**, *9*, 860–870. [[CrossRef](#)]
117. Jeong, J.Y.; Lim, S.; Sohn, J.H.; Lee, J.G.; Jun, D.W.; Kim, Y. Presence of Sarcopenia and Its Rate of Change Are Independently Associated with Long-Term Mortality in Patients with Liver Cirrhosis. *J. Korean Med. Sci.* **2018**, *33*, e299. [[CrossRef](#)] [[PubMed](#)]
118. Ebadi, M.; Tsien, C.; Bhanji, R.A.; Dunichand-Hoedl, A.R.; Rider, E.; Motamedrad, M.; Mazurak, V.C.; Baracos, V.; Montano-Loza, A.J. Skeletal Muscle Pathological Fat Infiltration (Myosteatorosis) Is Associated with Higher Mortality in Patients with Cirrhosis. *Cells* **2022**, *11*, 1345. [[CrossRef](#)] [[PubMed](#)]
119. Cai, W.; Lin, H.; Qi, R.; Lin, X.; Zhao, Y.; Chen, W.; Huang, Z. Psoas Muscle Density Predicts Occurrences of Hepatic Encephalopathy in Patients Receiving Transjugular Intrahepatic Portosystemic Shunts within 1 Year. *Cardiovasc. Interv. Radiol.* **2022**, *45*, 93–101. [[CrossRef](#)] [[PubMed](#)]



120. Wang, X.; Sun, M.; Li, Y.; Guo, G.; Yang, W.; Mao, L.; Yu, Z.; Hui, Y.; Fan, X.; Cui, B.; et al. Association of Myosteatosi s with Various Body Composition Abnormalities and Longer Length of Hospitalization in Patients with Decompensated Cirrhosis. *Front. Nutr.* **2022**, *9*, 921181. [[CrossRef](#)]
121. Alsebaey, A.; Sabry, A.; Rashed, H.S.; Elsabaawy, M.M.; Ragab, A.; Aly, R.A.; Badran, H. MELD-Sarcopenia Is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation. *Asian Pac. J. Cancer Prev. APJCP* **2021**, *22*, 2005–2009. [[CrossRef](#)] [[PubMed](#)]
122. Lattanzi, B.; Nardelli, S.; Pigliacelli, A.; Di Cola, S.; Farcomeni, A.; D’Ambrosio, D.; Gioia, S.; Ginanni Corradini, S.; Lucidi, C.; Mennini, G.; et al. The Additive Value of Sarcopenia, Myosteatosi s and Hepatic Encephalopathy in the Predictivity of Model for End-Stage Liver Disease. *Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver* **2019**, *51*, 1508–1512. [[CrossRef](#)]
123. Shoreibah, M.G.; Mahmoud, K.; Aboueldahab, N.A.; Vande Lune, P.; Massoud, M.; Bae, S.; El Khudari, H.; Gunn, A.J.; Abdel Aal, A.K. Psoas Muscle Density in Combination with Model for End-Stage Liver Disease Score Can Improve Survival Predictability in Transjugular Intrahepatic Portosystemic Shunts. *J. Vasc. Interv. Radiol. JVIR* **2019**, *30*, 154–161. [[CrossRef](#)] [[PubMed](#)]
124. Bai, Y.-W.; Liu, J.-C.; Yang, C.-T.; Wang, Y.-L.; Wang, C.-Y.; Ju, S.-G.; Zhou, C.; Huang, S.-J.; Li, T.-Q.; Chen, Y.; et al. Inclusion of Sarcopenia Improves the Prognostic Value of MELD Score in Patients after Transjugular Intrahepatic Portosystemic Shunt. *Eur. J. Gastroenterol. Hepatol.* **2022**, *34*, 948–955. [[CrossRef](#)]
125. Hentschel, F.; Schwarz, T.; Lüth, S.; Schreyer, A.G. Psoas Muscle Index Predicts Time to Rehospitalization in Liver Cirrhosis: An Observational Study. *Medicine* **2022**, *101*, e30259. [[CrossRef](#)]
126. Tapper, E.B.; Zhang, P.; Garg, R.; Nault, T.; Leary, K.; Krishnamurthy, V.; Su, G.L. Body Composition Predicts Mortality and Decompensation in Compensated Cirrhosis Patients: A Prospective Cohort Study. *JHEP Rep. Innov. Hepatol.* **2020**, *2*, 100061. [[CrossRef](#)] [[PubMed](#)]
127. Mauro, E.; Crespo, G.; Martinez-Garmendia, A.; Gutierrez-Acevedo, M.N.; Diaz, J.M.; Saidman, J.; Bermudez, C.; Ortiz-Patron, J.; Garcia-Oliveira, L.; Zalazar, F.; et al. Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List. *Transplantation* **2020**, *104*, e188–e198. [[CrossRef](#)] [[PubMed](#)]
128. Bot, D.; Droop, A.; Lucassen, C.J.; van Veen, M.E.; van Vugt, J.L.A.; Shahbazi Feshali, S.; Leistra, E.; Tushuizen, M.E.; van Hoek, B. Both Muscle Quantity and Quality Are Predictors of Waiting List Mortality in Patients with End-Stage Liver Disease. *Clin. Nutr. ESPEN* **2021**, *42*, 272–279. [[CrossRef](#)]
129. Kumar, V.V.; Kothakota, S.R.; Nair, A.K.; Sasidharan, M.; Kareem, H.; Kanala, J.; Kumar, C.P. Impact of Sarcopenia on Post-Liver Transplant Morbidity and Mortality in Cirrhotic Patients. *Indian J. Gastroenterol. Off. J. Indian Soc. Gastroenterol.* **2022**, *41*, 440–445. [[CrossRef](#)]
130. Ooi, P.H.; Hager, A.; Mazurak, V.C.; Dajani, K.; Bhargava, R.; Gilmour, S.M.; Mager, D.R. Sarcopenia in Chronic Liver Disease: Impact on Outcomes. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2019**, *25*, 1422–1438. [[CrossRef](#)]
131. Kumar, V.; Benjamin, J.; Shasthry, V.; Subramanya Bharathy, K.G.; Sinha, P.K.; Kumar, G.; Pamecha, V. Sarcopenia in Cirrhosis: Fallout on Liver Transplantation. *J. Clin. Exp. Hepatol.* **2020**, *10*, 467–476. [[CrossRef](#)] [[PubMed](#)]
132. Kalafateli, M.; Mantzoukis, K.; Choi Yau, Y.; Mohammad, A.O.; Arora, S.; Rodrigues, S.; de Vos, M.; Papadimitriou, K.; Thorburn, D.; O’Beirne, J.; et al. Malnutrition and Sarcopenia Predict Post-Liver Transplantation Outcomes Independently of the Model for End-Stage Liver Disease Score. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 113–121. [[CrossRef](#)]
133. Hey, P.; Hoermann, R.; Gow, P.; Hanrahan, T.P.; Testro, A.G.; Apostolov, R.; Sinclair, M. Reduced Upper Limb Lean Mass on Dual Energy X-Ray Absorptiometry Predicts Adverse Outcomes in Male Liver Transplant Recipients. *World J. Transplant.* **2022**, *12*, 120–130. [[CrossRef](#)]
134. Chapman, B.; Goh, S.K.; Parker, F.; Romero, S.; Sinclair, M.; Gow, P.; Ma, R.; Angus, P.; Jones, R.; Luke, J.; et al. Malnutrition and Low Muscle Strength Are Independent Predictors of Clinical Outcomes and Healthcare Costs after Liver Transplant. *Clin. Nutr. ESPEN* **2022**, *48*, 210–219. [[CrossRef](#)] [[PubMed](#)]
135. Kappus, M.R.; Wegermann, K.; Bozdogan, E.; Patel, Y.A.; Janas, G.; Shropshire, E.; Parish, A.; Niedzwiecki, D.; Muir, A.J.; Bashir, M. Use of Skeletal Muscle Index as a Predictor of Wait-List Mortality in Patients with End-Stage Liver Disease. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2020**, *26*, 1090–1099. [[CrossRef](#)]
136. Fozouni, L.; Mohamad, Y.; Lebsack, A.; Freise, C.; Stock, P.; Lai, J.C. Frailty Is Associated with Increased Rates of Acute Cellular Rejection within 3 Months after Liver Transplantation. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2020**, *26*, 390–396. [[CrossRef](#)]
137. Aby, E.S.; Lee, E.; Saggi, S.S.; Viramontes, M.R.; Grotts, J.F.; Agopian, V.G.; Busuttill, R.W.; Saab, S. Pretransplant Sarcopenia in Patients with NASH Cirrhosis Does Not Impact Rehospitalization or Mortality. *J. Clin. Gastroenterol.* **2019**, *53*, 680–685. [[CrossRef](#)] [[PubMed](#)]
138. Chun, H.S.; Lee, M.; Lee, H.A.; Lee, S.; Kim, S.; Jung, Y.J.; Lee, C.; Kim, H.; Lee, H.A.; Kim, H.Y.; et al. Risk Stratification for Sarcopenic Obesity in Subjects with Nonalcoholic Fatty Liver Disease. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2022**, *in press*. [[CrossRef](#)]
139. Choe, E.Y.; Lee, Y.-H.; Choi, Y.J.; Huh, B.W.; Lee, B.-W.; Kim, S.-K.; Kang, E.S.; Cha, B.-S.; Lee, E.J.; Huh, K.B.; et al. Waist-to-Calf Circumstance Ratio Is an Independent Predictor of Hepatic Steatosis and Fibrosis in Patients with Type 2 Diabetes. *J. Gastroenterol. Hepatol.* **2018**, *33*, 1082–1091. [[CrossRef](#)]

140. Shida, T.; Oshida, N.; Oh, S.; Okada, K.; Shoda, J. Progressive Reduction in Skeletal Muscle Mass to Visceral Fat Area Ratio Is Associated with a Worsening of the Hepatic Conditions of Non-Alcoholic Fatty Liver Disease. *Diabetes Metab. Syndr. Obes. Targets Ther.* **2019**, *12*, 495–503. [[CrossRef](#)]
141. Su, X.; Xu, J.; Zheng, C. The Relationship between Non-Alcoholic Fatty Liver and Skeletal Muscle Mass to Visceral Fat Area Ratio in Women with Type 2 Diabetes. *BMC Endocr. Disord.* **2019**, *19*, 76. [[CrossRef](#)] [[PubMed](#)]
142. Cho, Y.; Chang, Y.; Ryu, S.; Jung, H.-S.; Kim, C.-W.; Oh, H.; Kim, M.K.; Sohn, W.; Shin, H.; Wild, S.H.; et al. Skeletal Muscle Mass to Visceral Fat Area Ratio as a Predictor of NAFLD in Lean and Overweight Men and Women with Effect Modification by Sex. *Hepatol. Commun.* **2022**, *6*, 2238–2252. [[CrossRef](#)] [[PubMed](#)]
143. Shi, Y.-X.; Chen, X.-Y.; Qiu, H.-N.; Jiang, W.-R.; Zhang, M.-Y.; Huang, Y.-P.; Ji, Y.-P.; Zhang, S.; Li, C.-J.; Lin, J.-N. Visceral Fat Area to Appendicular Muscle Mass Ratio as a Predictor for Nonalcoholic Fatty Liver Disease Independent of Obesity. *Scand. J. Gastroenterol.* **2021**, *56*, 312–320. [[CrossRef](#)] [[PubMed](#)]
144. Li, G.; Rios, R.S.; Wang, X.-X.; Yu, Y.; Zheng, K.I.; Huang, O.-Y.; Tang, L.-J.; Ma, H.-L.; Jin, Y.; Targher, G.; et al. Sex Influences the Association between Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio and Non-Alcoholic Steatohepatitis in Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease. *Br. J. Nutr.* **2021**, *127*, 1613–1620. [[CrossRef](#)] [[PubMed](#)]
145. Kashiwagi, K.; Takayama, M.; Fukuhara, K.; Shimizu-Hirota, R.; Chu, P.-S.; Nakamoto, N.; Inoue, N.; Iwao, Y.; Kanai, T. A Significant Association of Non-Obese Non-Alcoholic Fatty Liver Disease with Sarcopenic Obesity. *Clin. Nutr. ESPEN* **2020**, *38*, 86–93. [[CrossRef](#)]
146. Wijarnpreecha, K.; Aby, E.S.; Ahmed, A.; Kim, D. Association between Sarcopenic Obesity and Nonalcoholic Fatty Liver Disease and Fibrosis Detected by Fibroscan. *J. Gastrointest. Liver Dis. JGLD* **2021**, *30*, 227–232. [[CrossRef](#)]
147. Kaibori, M.; Ishizaki, M.; Iida, H.; Matsui, K.; Sakaguchi, T.; Inoue, K.; Mizuta, T.; Ide, Y.; Iwasaka, J.; Kimura, Y.; et al. Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection. *J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract* **2015**, *19*, 1315–1323. [[CrossRef](#)]
148. Carias, S.; Castellanos, A.L.; Vilchez, V.; Nair, R.; Dela Cruz, A.C.; Watkins, J.; Barrett, T.; Trushar, P.; Esser, K.; Gedaly, R. Nonalcoholic Steatohepatitis Is Strongly Associated with Sarcopenic Obesity in Patients with Cirrhosis Undergoing Liver Transplant Evaluation. *J. Gastroenterol. Hepatol.* **2016**, *31*, 628–633. [[CrossRef](#)] [[PubMed](#)]
149. Kobayashi, A.; Kaido, T.; Hamaguchi, Y.; Okumura, S.; Shirai, H.; Yao, S.; Kamo, N.; Yagi, S.; Taura, K.; Okajima, H.; et al. Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. *Ann. Surg.* **2019**, *269*, 924–931. [[CrossRef](#)]
150. Hammad, A.; Kaido, T.; Hamaguchi, Y.; Okumura, S.; Kobayashi, A.; Shirai, H.; Kamo, N.; Yagi, S.; Uemoto, S. Impact of Sarcopenic Overweight on the Outcomes after Living Donor Liver Transplantation. *Hepatobiliary Surg. Nutr.* **2017**, *6*, 367–378. [[CrossRef](#)]
151. Hegyi, P.J.; Soós, A.; Hegyi, P.; Szakács, Z.; Hanák, L.; Vánca, S.; Ocskay, K.; Pétervári, E.; Balaskó, M.; Eröss, B.; et al. Pre-Transplant Sarcopenic Obesity Worsens the Survival after Liver Transplantation: A Meta-Analysis and a Systematic Review. *Front. Med.* **2020**, *7*, 599434. [[CrossRef](#)]
152. Ha, N.B.; Montano-Loza, A.J.; Carey, E.J.; Lin, S.; Shui, A.M.; Huang, C.-Y.; Dunn, M.A.; Lai, J.C. Sarcopenic Visceral Obesity Is Associated with Increased Post-Liver Transplant Mortality in Acutely Ill Patients with Cirrhosis. *Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg.* **2022**, *22*, 2195–2202. [[CrossRef](#)]
153. Hiraoka, A.; Nagamatsu, K.; Izumoto, H.; Yoshino, T.; Adachi, T.; Tsuruta, M.; Aibiki, T.; Okudaira, T.; Yamago, H.; Suga, Y.; et al. SARC-F Combined with a Simple Tool for Assessment of Muscle Abnormalities in Outpatients with Chronic Liver Disease. *Hepatol. Res. Off. J. Jpn. Soc. Hepatol.* **2020**, *50*, 502–511. [[CrossRef](#)] [[PubMed](#)]
154. Zhai, Y.; Xiao, Q.; Miao, J. The Relationship between NAFLD and Sarcopenia in Elderly Patients. *Can. J. Gastroenterol. Hepatol.* **2018**, *2018*, 5016091. [[CrossRef](#)]
155. Nishikawa, H.; Shiraki, M.; Hiramatsu, A.; Moriya, K.; Hino, K.; Nishiguchi, S. Japan Society of Hepatology Guidelines for Sarcopenia in Liver Disease (1st Edition): Recommendation from the Working Group for Creation of Sarcopenia Assessment Criteria. *Hepatol. Res.* **2016**, *46*, 951–963. [[CrossRef](#)]
156. Choe, E.K.; Kang, H.Y.; Park, B.; Yang, J.I.; Kim, J.S. The Association between Nonalcoholic Fatty Liver Disease and CT-Measured Skeletal Muscle Mass. *J. Clin. Med.* **2018**, *7*, 310. [[CrossRef](#)] [[PubMed](#)]
157. Ebadi, M.; Wang, C.W.; Lai, J.C.; Dasarathy, S.; Kappus, M.R.; Dunn, M.A.; Carey, E.J.; Montano-Loza, A.J. Poor Performance of Psoas Muscle Index for Identification of Patients with Higher Waitlist Mortality Risk in Cirrhosis. *J. Cachexia Sarcopenia Muscle* **2018**, *9*, 1053–1062. [[CrossRef](#)]
158. Gu, D.H.; Kim, M.Y.; Seo, Y.S.; Kim, S.G.; Lee, H.A.; Kim, T.H.; Jung, Y.K.; Kandemir, A.; Kim, J.H.; An, H.; et al. Clinical Usefulness of Psoas Muscle Thickness for the Diagnosis of Sarcopenia in Patients with Liver Cirrhosis. *Clin. Mol. Hepatol.* **2018**, *24*, 319–330. [[CrossRef](#)] [[PubMed](#)]
159. Praktijnjo, M.; Book, M.; Luetkens, J.; Pohlmann, A.; Meyer, C.; Thomas, D.; Jansen, C.; Feist, A.; Chang, J.; Grimm, J.; et al. Fat-Free Muscle Mass in Magnetic Resonance Imaging Predicts Acute-on-Chronic Liver Failure and Survival in Decompensated Cirrhosis. *Hepatology* **2018**, *67*, 1014–1026. [[CrossRef](#)] [[PubMed](#)]
160. Hong, H.C.; Hwang, S.Y.; Choi, H.Y.; Yoo, H.J.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Baik, S.H.; Choi, D.S.; Choi, K.M. Relationship between Sarcopenia and Nonalcoholic Fatty Liver Disease: The Korean Sarcopenic Obesity Study. *Hepatology* **2014**, *59*, 1772–1778. [[CrossRef](#)]

161. Sinclair, M.; Chapman, B.; Hoermann, R.; Angus, P.W.; Testro, A.; Scodellaro, T.; Gow, P.J. Handgrip Strength Adds More Prognostic Value to the Model for End-Stage Liver Disease Score Than Imaging-Based Measures of Muscle Mass in Men with Cirrhosis. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2019**, *25*, 1480–1487. [[CrossRef](#)] [[PubMed](#)]
162. Sinclair, M.; Hoermann, R.; Peterson, A.; Testro, A.; Angus, P.W.; Hey, P.; Chapman, B.; Gow, P.J. Use of Dual X-Ray Absorptiometry in Men with Advanced Cirrhosis to Predict Sarcopenia-Associated Mortality Risk. *Liver Int. Off. J. Int. Assoc. Study Liver* **2019**, *39*, 1089–1097. [[CrossRef](#)]
163. Belarmino, G.; Gonzalez, M.C.; Sala, P.; Torrinhas, R.S.; Andraus, W.; D’Albuquerque, L.A.C.; Pereira, R.M.R.; Caparbo, V.F.; Ferrioli, E.; Pfrimer, K.; et al. Diagnosing Sarcopenia in Male Patients with Cirrhosis by Dual-Energy X-Ray Absorptiometry Estimates of Appendicular Skeletal Muscle Mass. *JPEN J. Parenter. Enter. Nutr.* **2018**, *42*, 24–36. [[CrossRef](#)] [[PubMed](#)]
164. Eriksen, C.S.; Kimer, N.; Suetta, C.; Møller, S. Arm Lean Mass Determined by Dual-Energy X-Ray Absorptiometry Is Superior to Characterize Skeletal Muscle and Predict Sarcopenia-Related Mortality in Cirrhosis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2021**, *320*, G729–G740. [[CrossRef](#)]
165. Lee, Y.-H.; Jung, K.S.; Kim, S.U.; Yoon, H.-J.; Yun, Y.J.; Lee, B.-W.; Kang, E.S.; Han, K.-H.; Lee, H.C.; Cha, B.-S. Sarcopenia Is Associated with NAFLD Independently of Obesity and Insulin Resistance: Nationwide Surveys (KNHANES 2008–2011). *J. Hepatol.* **2015**, *63*, 486–493. [[CrossRef](#)]
166. Roh, E.; Hwang, S.Y.; Yoo, H.J.; Baik, S.H.; Lee, J.-H.; Son, S.J.; Kim, H.J.; Park, Y.S.; Lee, S.-G.; Cho, B.L.; et al. Impact of Non-Alcoholic Fatty Liver Disease on the Risk of Sarcopenia: A Nationwide Multicenter Prospective Study. *Hepatol. Int.* **2022**, *16*, 545–554. [[CrossRef](#)] [[PubMed](#)]
167. Santos, L.A.A.; Lima, T.B.; Qi, X.; de Paiva, S.A.R.; Romeiro, F.G. Refining Dual-Energy x-Ray Absorptiometry Data to Predict Mortality among Cirrhotic Outpatients: A Retrospective Study. *Nutrition* **2021**, *85*, 111132. [[CrossRef](#)] [[PubMed](#)]
168. Pan, X.-Y.; Liu, W.-Y.; Zhu, P.-W.; Li, G.; Tang, L.-J.; Gao, F.; Huang, O.-Y.; Yuan, H.-Y.; Targher, G.; Byrne, C.D.; et al. Low Skeletal Muscle Mass Is Associated with More Severe Histological Features of Non-Alcoholic Fatty Liver Disease in Male. *Hepatol. Int.* **2022**, *16*, 1085–1093. [[CrossRef](#)]
169. Peng, T.-C.; Wu, L.-W.; Chen, W.-L.; Liaw, F.-Y.; Chang, Y.-W.; Kao, T.-W. Nonalcoholic Fatty Liver Disease and Sarcopenia in a Western Population (NHANES III): The Importance of Sarcopenia Definition. *Clin. Nutr.* **2019**, *38*, 422–428. [[CrossRef](#)]
170. Song, W.; Yoo, S.H.; Jang, J.; Baik, S.J.; Lee, B.K.; Lee, H.W.; Park, J.S. Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis. *Gut Liver* **2022**, *17*, 130–138. [[CrossRef](#)]
171. Seo, J.Y.; Cho, E.J.; Kim, M.J.; Kwak, M.-S.; Yang, J.I.; Chung, S.J.; Yim, J.Y.; Yoon, J.W.; Chung, G.E. The Relationship between Metabolic Dysfunction-Associated Fatty Liver Disease and Low Muscle Mass in an Asymptomatic Korean Population. *J. Cachexia Sarcopenia Muscle* **2022**, *13*, 2953–2960. [[CrossRef](#)] [[PubMed](#)]
172. Nishikawa, H.; Enomoto, H.; Iwata, Y.; Nishimura, T.; Iijima, H.; Nishiguchi, S. Clinical Utility of Bioimpedance Analysis in Liver Cirrhosis. *J. Hepato-Biliary-Pancreat. Sci.* **2017**, *24*, 409–416. [[CrossRef](#)]
173. do Espirito Santo Silva, D.; Waitzberg, D.L.; de Jesus, R.P.; de Oliveira, L.P.M.; Torrinhas, R.S.; Belarmino, G. Phase Angle as a Marker for Sarcopenia in Cirrhosis. *Clin. Nutr. ESPEN* **2019**, *32*, 56–60. [[CrossRef](#)]
174. Ruiz-Margáin, A.; Xie, J.J.; Román-Calleja, B.M.; Pauly, M.; White, M.G.; Chapa-Ibargüenitoia, M.; Campos-Murguía, A.; González-Regueiro, J.A.; Macías-Rodríguez, R.U.; Duarte-Rojo, A. Phase Angle From Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis with or without Ascites. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2021**, *19*, 1941–1949.e2. [[CrossRef](#)]
175. Alvares-da-Silva, M.R.; Reverbel da Silveira, T. Comparison between Handgrip Strength, Subjective Global Assessment, and Prognostic Nutritional Index in Assessing Malnutrition and Predicting Clinical Outcome in Cirrhotic Outpatients. *Nutrition* **2005**, *21*, 113–117. [[CrossRef](#)] [[PubMed](#)]
176. Daphnee, D.K.; John, S.; Vaidya, A.; Khakhar, A.; Bhuvaneshwari, S.; Ramamurthy, A. Hand Grip Strength: A Reliable, Reproducible, Cost-Effective Tool to Assess the Nutritional Status and Outcomes of Cirrhotics Awaiting Liver Transplant. *Clin. Nutr. ESPEN* **2017**, *19*, 49–53. [[CrossRef](#)]
177. De, A.; Kumari, S.; Kaur, A.; Singh, A.; Kalra, N.; Singh, V. Hand-Grip Strength as a Screening Tool for Sarcopenia in Males with Decompensated Cirrhosis. *Indian J. Gastroenterol. Off. J. Indian Soc. Gastroenterol.* **2022**, *41*, 284–291. [[CrossRef](#)] [[PubMed](#)]
178. Abrams, H.L.; McNeil, B.J. Medical Implications of Computed Tomography (“CAT Scanning”) (First of Two Parts). *N. Engl. J. Med.* **1978**, *298*, 255–261. [[CrossRef](#)]
179. Wang, F.-Z.; Sun, H.; Zhou, J.; Sun, L.-L.; Pan, S.-N. Reliability and Validity of Abdominal Skeletal Muscle Area Measurement Using Magnetic Resonance Imaging. *Acad. Radiol.* **2021**, *28*, 1692–1698. [[CrossRef](#)]
180. Romeiro, F.G.; Augusti, L. Nutritional Assessment in Cirrhotic Patients with Hepatic Encephalopathy. *World J. Hepatol.* **2015**, *7*, 2940–2954. [[CrossRef](#)]
181. Newman, A.B.; Kupelian, V.; Visser, M.; Simonsick, E.; Goodpaster, B.; Nevitt, M.; Kritchevsky, S.B.; Tylavsky, F.A.; Rubin, S.M.; Harris, T.B. Sarcopenia: Alternative Definitions and Associations with Lower Extremity Function. *J. Am. Geriatr. Soc.* **2003**, *51*, 1602–1609. [[CrossRef](#)]
182. Shaw, K.A.; Srikanth, V.K.; Fryer, J.L.; Blizzard, L.; Dwyer, T.; Venn, A.J. Dual Energy X-Ray Absorptiometry Body Composition and Aging in a Population-Based Older Cohort. *Int. J. Obes.* **2007**, *31*, 279–284. [[CrossRef](#)] [[PubMed](#)]



183. Ebadi, M.; Montano-Loza, A.J. Clinical Relevance of Skeletal Muscle Abnormalities in Patients with Cirrhosis. *Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver* **2019**, *51*, 1493–1499. [[CrossRef](#)] [[PubMed](#)]
184. Merli, M.; Berzigotti, A.; Zelber-Sagi, S.; Dasarathy, S.; Montagnese, S.; Genton, L.; Plauth, M.; Parés, A. EASL Clinical Practice Guidelines on Nutrition in Chronic Liver Disease. *J. Hepatol.* **2019**, *70*, 172–193. [[CrossRef](#)]
185. Sempokuya, T.; Yokoyama-Arakaki, L.; Wong, L.L.; Kalathil, S. A Pilot Study of Racial Differences in the Current Definition of Sarcopenia among Liver Transplant Candidates. *Hawai'i J. Health Soc. Welf.* **2020**, *79*, 161–167.
186. Chen, L.-K.; Liu, L.-K.; Woo, J.; Assantachai, P.; Auyeung, T.-W.; Bahyah, K.S.; Chou, M.-Y.; Chen, L.-Y.; Hsu, P.-S.; Krairit, O.; et al. Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia. *J. Am. Med. Dir. Assoc.* **2014**, *15*, 95–101. [[CrossRef](#)] [[PubMed](#)]
187. Hou, J.C.; Zhang, Y.M.; Qiang, Z.; Zhu, L.Y.; Zheng, H.; Shen, Z.Y. The Psoas Muscle Depletion Index Is Related to the Degree of Cirrhosis and Skeletal Muscle Loss in Patients with End-Stage Liver Disease. *Acta Gastro-Enterol. Belg.* **2022**, *85*, 453–462. [[CrossRef](#)]
188. Lee, Y.J.; Lee, J.M.; Lee, J.S.; Lee, H.Y.; Park, B.H.; Kim, Y.H.; Han, J.K.; Choi, B.I. Hepatocellular Carcinoma: Diagnostic Performance of Multidetector CT and MR Imaging—a Systematic Review and Meta-Analysis. *Radiology* **2015**, *275*, 97–109. [[CrossRef](#)]
189. Borga, M.; West, J.; Bell, J.D.; Harvey, N.C.; Romu, T.; Heymsfield, S.B.; Dahlqvist Leinhard, O. Advanced Body Composition Assessment: From Body Mass Index to Body Composition Profiling. *J. Investig. Med.* **2018**, *66*, 887–895. [[CrossRef](#)]
190. Schweitzer, L.; Geisler, C.; Pourhassan, M.; Braun, W.; Glüer, C.-C.; Bony-Westphal, A.; Müller, M.J. What Is the Best Reference Site for a Single MRI Slice to Assess Whole-Body Skeletal Muscle and Adipose Tissue Volumes in Healthy Adults? *Am. J. Clin. Nutr.* **2015**, *102*, 58–65. [[CrossRef](#)]
191. Tandon, P.; Mourtzakis, M.; Low, G.; Zenith, L.; Ney, M.; Carbonneau, M.; Alaboudy, A.; Mann, S.; Esfandiari, N.; Ma, M. Comparing the Variability Between Measurements for Sarcopenia Using Magnetic Resonance Imaging and Computed Tomography Imaging. *Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg.* **2016**, *16*, 2766–2767. [[CrossRef](#)]
192. Surov, A.; Paul, L.; Meyer, H.J.; Schob, S.; Engelmann, C.; Wienke, A. Apparent Diffusion Coefficient Is a Novel Imaging Biomarker of Myopathic Changes in Liver Cirrhosis. *J. Clin. Med.* **2018**, *7*, 359. [[CrossRef](#)]
193. Strauss, B.J.; Gibson, P.R.; Stroud, D.B.; Borovnicar, D.J.; Xiong, D.W.; Keogh, J. Total Body Dual X-Ray Absorptiometry Is a Good Measure of Both Fat Mass and Fat-Free Mass in Liver Cirrhosis Compared to “Gold-Standard” Techniques. Melbourne Liver Group. *Ann. N. Y. Acad. Sci.* **2000**, *904*, 55–62. [[CrossRef](#)] [[PubMed](#)]
194. Orkin, S.; Yodoshi, T.; Romantic, E.; Hitchcock, K.; Arce-Clachar, A.C.; Bramlage, K.; Sun, Q.; Fei, L.; Xanthakos, S.A.; Trout, A.T.; et al. Body Composition Measured by Bioelectrical Impedance Analysis Is a Viable Alternative to Magnetic Resonance Imaging in Children with Nonalcoholic Fatty Liver Disease. *JPEN J. Parenter. Enter. Nutr.* **2022**, *46*, 378–384. [[CrossRef](#)] [[PubMed](#)]
195. Pirlich, M.; Schütz, T.; Spachos, T.; Ertl, S.; Weiß, M.-L.; Lochs, H.; Plauth, M. Bioelectrical Impedance Analysis Is a Useful Bedside Technique to Assess Malnutrition in Cirrhotic Patients with and without Ascites. *Hepatology* **2000**, *32*, 1208–1215. [[CrossRef](#)]
196. Luengpradidgun, L.; Chamroonkul, N.; Sripongpan, P.; Kaewdech, A.; Tanutit, P.; Ina, N.; Piratvisuth, T. Utility of Handgrip Strength (HGS) and Bioelectrical Impedance Analysis (BIA) in the Diagnosis of Sarcopenia in Cirrhotic Patients. *BMC Gastroenterol.* **2022**, *22*, 159. [[CrossRef](#)]
197. Tandon, P.; Low, G.; Mourtzakis, M.; Zenith, L.; Myers, R.P.; Abraldes, J.G.; Shaheen, A.A.M.; Qamar, H.; Mansoor, N.; Carbonneau, M.; et al. A Model to Identify Sarcopenia in Patients with Cirrhosis. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2016**, *14*, 1473–1480.e3. [[CrossRef](#)]
198. Ciocirlan, M.; Mănuș, M.; Dicușescu, M.; Ciocirlan, M. Is Rectus Abdominis Thickness Associated with Survival among Patients with Liver Cirrhosis? A Prospective Cohort Study. *Sao Paulo Med. J. = Rev. Paul. De Med.* **2019**, *137*, 401–406. [[CrossRef](#)] [[PubMed](#)]
199. Hari, A.; Berzigotti, A.; Štabuc, B.; Caglevič, N. Muscle Psoas Indices Measured by Ultrasound in Cirrhosis—Preliminary Evaluation of Sarcopenia Assessment and Prediction of Liver Decompensation and Mortality. *Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver* **2019**, *51*, 1502–1507. [[CrossRef](#)]
200. Woodward, A.J.; Wallen, M.P.; Ryan, J.; Ward, L.C.; Coombes, J.S.; Macdonald, G.A. Evaluation of Techniques Used to Assess Skeletal Muscle Quantity in Patients with Cirrhosis. *Clin. Nutr. ESPEN* **2021**, *44*, 287–296. [[CrossRef](#)] [[PubMed](#)]
201. Dunn, M.A.; Josbeno, D.A.; Tevar, A.D.; Rachakonda, V.; Ganesh, S.R.; Schmotzer, A.R.; Kallenborn, E.A.; Behari, J.; Landsittel, D.P.; DiMartini, A.F.; et al. Frailty as Tested by Gait Speed Is an Independent Risk Factor for Cirrhosis Complications That Require Hospitalization. *Am. J. Gastroenterol.* **2016**, *111*, 1768–1775. [[CrossRef](#)] [[PubMed](#)]
202. Lai, J.C.; Feng, S.; Terrault, N.A.; Lizaola, B.; Hayssen, H.; Covinsky, K. Frailty Predicts Waitlist Mortality in Liver Transplant Candidates. *Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg.* **2014**, *14*, 1870–1879. [[CrossRef](#)] [[PubMed](#)]
203. Yadav, A.; Chang, Y.-H.; Carpenter, S.; Silva, A.C.; Rakela, J.; Aqel, B.A.; Byrne, T.J.; Douglas, D.D.; Vargas, H.E.; Carey, E.J. Relationship between Sarcopenia, Six-Minute Walk Distance and Health-Related Quality of Life in Liver Transplant Candidates. *Clin. Transplant.* **2015**, *29*, 134–141. [[CrossRef](#)] [[PubMed](#)]
204. Bischoff, S.C.; Bernal, W.; Dasarathy, S.; Merli, M.; Plank, L.D.; Schütz, T.; Plauth, M. ESPEN Practical Guideline: Clinical Nutrition in Liver Disease. *Clin. Nutr.* **2020**, *39*, 3533–3562. [[CrossRef](#)]
205. Long, M.T.; Noureddin, M.; Lim, J.K. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. *Gastroenterology* **2022**, *163*, 764–774.e1. [[CrossRef](#)]

206. Bischoff, S.C.; Barazzoni, R.; Busetto, L.; Campmans-Kuijpers, M.; Cardinale, V.; Chermesh, I.; Eshraghian, A.; Kani, H.T.; Khannoussi, W.; Lacaze, L.; et al. European Guideline on Obesity Care in Patients with Gastrointestinal and Liver Diseases—Joint ESPEN/UEG Guideline. *Clin. Nutr.* **2022**, *41*, 2364–2405. [[CrossRef](#)]
207. Wycherley, T.P.; Moran, L.J.; Clifton, P.M.; Noakes, M.; Brinkworth, G.D. Effects of Energy-Restricted High-Protein, Low-Fat Compared with Standard-Protein, Low-Fat Diets: A Meta-Analysis of Randomized Controlled Trials. *Am. J. Clin. Nutr.* **2012**, *96*, 1281–1298. [[CrossRef](#)]
208. Muscariello, E.; Nasti, G.; Siervo, M.; Di Maro, M.; Lapi, D.; D’Addio, G.; Colantuoni, A. Dietary Protein Intake in Sarcopenic Obese Older Women. *Clin. Interv. Aging* **2016**, *11*, 133–140. [[CrossRef](#)]
209. Sammarco, R.; Marra, M.; Di Guglielmo, M.L.; Naccarato, M.; Contaldo, F.; Poggiogalle, E.; Donini, L.M.; Pasanisi, F. Evaluation of Hypocaloric Diet with Protein Supplementation in Middle-Aged Sarcopenic Obese Women: A Pilot Study. *Obes. Facts* **2017**, *10*, 160–167. [[CrossRef](#)]
210. Dent, E.; Morley, J.E.; Cruz-Jentoft, A.J.; Arai, H.; Kritchevsky, S.B.; Guralnik, J.; Bauer, J.M.; Pahor, M.; Clark, B.C.; Cesari, M.; et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. *J. Nutr. Health Aging* **2018**, *22*, 1148–1161. [[CrossRef](#)]
211. Beaudart, C.; Dawson, A.; Shaw, S.C.; Harvey, N.C.; Kanis, J.A.; Binkley, N.; Reginster, J.Y.; Chapurlat, R.; Chan, D.C.; Bruyère, O.; et al. Nutrition and Physical Activity in the Prevention and Treatment of Sarcopenia: Systematic Review. *Osteoporos. Int. A J. Establ. Result Coop. Between Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA* **2017**, *28*, 1817–1833. [[CrossRef](#)]
212. De Spiegeleer, A.; Petrovic, M.; Boeckxstaens, P.; Van Den Noortgate, N. Treating Sarcopenia in Clinical Practice: Where Are We Now? *Acta Clin. Belg.* **2016**, *71*, 197–205. [[CrossRef](#)] [[PubMed](#)]
213. Hsu, K.-J.; Liao, C.-D.; Tsai, M.-W.; Chen, C.-N. Effects of Exercise and Nutritional Intervention on Body Composition, Metabolic Health, and Physical Performance in Adults with Sarcopenic Obesity: A Meta-Analysis. *Nutrients* **2019**, *11*, 2163. [[CrossRef](#)] [[PubMed](#)]
214. Sardeli, A.V.; Komatsu, T.R.; Mori, M.A.; Gáspari, A.F.; Chacon-Mikahil, M.P.T. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. *Nutrients* **2018**, *10*, 423. [[CrossRef](#)]
215. Swift, D.L.; McGee, J.E.; Earnest, C.P.; Carlisle, E.; Nygard, M.; Johannsen, N.M. The Effects of Exercise and Physical Activity on Weight Loss and Maintenance. *Prog. Cardiovasc. Dis.* **2018**, *61*, 206–213. [[CrossRef](#)] [[PubMed](#)]
216. Curioni, C.C.; Lourenço, P.M. Long-Term Weight Loss after Diet and Exercise: A Systematic Review. *Int. J. Obes.* **2005**, *29*, 1168–1174. [[CrossRef](#)] [[PubMed](#)]
217. Johns, D.J.; Hartmann-Boyce, J.; Jebb, S.A.; Aveyard, P. Diet or Exercise Interventions vs Combined Behavioral Weight Management Programs: A Systematic Review and Meta-Analysis of Direct Comparisons. *J. Acad. Nutr. Diet.* **2014**, *114*, 1557–1568. [[CrossRef](#)]
218. Linden, M.A.; Sheldon, R.D.; Meers, G.M.; Ortinau, L.C.; Morris, E.M.; Booth, F.W.; Kanaley, J.A.; Vieira-Potter, V.J.; Sowers, J.R.; Ibdah, J.A.; et al. Aerobic Exercise Training in the Treatment of Non-Alcoholic Fatty Liver Disease Related Fibrosis. *J. Physiol.* **2016**, *594*, 5271–5284. [[CrossRef](#)]
219. Hashida, R.; Kawaguchi, T.; Bekki, M.; Omoto, M.; Matsuse, H.; Nago, T.; Takano, Y.; Ueno, T.; Koga, H.; George, J.; et al. Aerobic vs. Resistance Exercise in Non-Alcoholic Fatty Liver Disease: A Systematic Review. *J. Hepatol.* **2017**, *66*, 142–152. [[CrossRef](#)] [[PubMed](#)]
220. Chun, H.S.; Lee, M.; Lee, H.A.; Oh, S.Y.; Baek, H.J.; Moon, J.W.; Kim, Y.J.; Lee, J.; Kim, H.; Kim, H.Y.; et al. Association of Physical Activity with Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2022**, *21*, 358–369.e12. [[CrossRef](#)] [[PubMed](#)]
221. Gonzalez, A.; Valero-Breton, M.; Huerta-Salgado, C.; Achiardi, O.; Simon, F.; Cabello-Verrugio, C. Impact of Exercise Training on the Sarcopenia Criteria in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Eur. J. Transl. Myol.* **2021**, *31*, 9630. [[CrossRef](#)]
222. Román, E.; García-Galcerán, C.; Torrades, T.; Herrera, S.; Marín, A.; Doñate, M.; Alvarado-Tapias, E.; Malouf, J.; Nacher, L.; Serra-Grima, R.; et al. Effects of an Exercise Programme on Functional Capacity, Body Composition and Risk of Falls in Patients with Cirrhosis: A Randomized Clinical Trial. *PLoS ONE* **2016**, *11*, e0151652. [[CrossRef](#)]
223. Aamann, L.; Dam, G.; Borre, M.; Drljevic-Nielsen, A.; Overgaard, K.; Andersen, H.; Vilstrup, H.; Aagaard, N.K. Resistance Training Increases Muscle Strength and Muscle Size in Patients with Liver Cirrhosis. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2020**, *18*, 1179–1187.e6. [[CrossRef](#)] [[PubMed](#)]
224. Williams, F.R.; Berzigotti, A.; Lord, J.M.; Lai, J.C.; Armstrong, M.J. Review Article: Impact of Exercise on Physical Frailty in Patients with Chronic Liver Disease. *Aliment. Pharmacol. Ther.* **2019**, *50*, 988–1000. [[CrossRef](#)]
225. Debette-Gratien, M.; Tabouret, T.; Antonini, M.-T.; Dalmay, F.; Carrier, P.; Legros, R.; Jacques, J.; Vincent, F.; Sautereau, D.; Samuel, D.; et al. Personalized Adapted Physical Activity before Liver Transplantation: Acceptability and Results. *Transplantation* **2015**, *99*, 145–150. [[CrossRef](#)] [[PubMed](#)]
226. Zenith, L.; Meena, N.; Ramadi, A.; Yavari, M.; Harvey, A.; Carbonneau, M.; Ma, M.; Abraldes, J.G.; Paterson, I.; Haykowsky, M.J.; et al. Eight Weeks of Exercise Training Increases Aerobic Capacity and Muscle Mass and Reduces Fatigue in Patients with Cirrhosis. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2014**, *12*, 1920–1926.e2. [[CrossRef](#)]
227. Kruger, C.; McNeely, M.L.; Bailey, R.J.; Yavari, M.; Abraldes, J.G.; Carbonneau, M.; Newnham, K.; DenHeyer, V.; Ma, M.; Thompson, R.; et al. Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence. *Sci. Rep.* **2018**, *8*, 99. [[CrossRef](#)]

228. Williams, F.R.; Vallance, A.; Faulkner, T.; Towey, J.; Durman, S.; Kyte, D.; Elsharkawy, A.M.; Perera, T.; Holt, A.; Ferguson, J.; et al. Home-Based Exercise in Patients Awaiting Liver Transplantation: A Feasibility Study. *Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc.* **2019**, *25*, 995–1006. [[CrossRef](#)]
229. Chen, H.W.; Ferrando, A.; White, M.G.; Dennis, R.A.; Xie, J.; Pauly, M.; Park, S.; Bartter, T.; Dunn, M.A.; Ruiz-Margain, A.; et al. Home-Based Physical Activity and Diet Intervention to Improve Physical Function in Advanced Liver Disease: A Randomized Pilot Trial. *Dig. Dis. Sci.* **2020**, *65*, 3350–3359. [[CrossRef](#)]
230. Brustia, R.; Savier, E.; Scatton, O. Physical Exercise in Cirrhotic Patients: Towards Prehabilitation on Waiting List for Liver Transplantation. A Systematic Review and Meta-Analysis. *Clin. Res. Hepatol. Gastroenterol.* **2018**, *42*, 205–215. [[CrossRef](#)]
231. Kobayashi, H.; Kato, H.; Hirabayashi, Y.; Murakami, H.; Suzuki, H. Modulations of Muscle Protein Metabolism by Branched-Chain Amino Acids in Normal and Muscle-Atrophiing Rats. *J. Nutr.* **2006**, *136*, 234S–236S. [[CrossRef](#)] [[PubMed](#)]
232. Jackman, S.R.; Witard, O.C.; Philp, A.; Wallis, G.A.; Baar, K.; Tipton, K.D. Branched-Chain Amino Acid Ingestion Stimulates Muscle Myofibrillar Protein Synthesis Following Resistance Exercise in Humans. *Front. Physiol.* **2017**, *8*, 390. [[CrossRef](#)] [[PubMed](#)]
233. Singh Tejavath, A.; Mathur, A.; Nathiya, D.; Singh, P.; Raj, P.; Suman, S.; Mundada, P.R.; Atif, S.; Rai, R.R.; Tomar, B.S. Impact of Branched Chain Amino Acid on Muscle Mass, Muscle Strength, Physical Performance, Combined Survival, and Maintenance of Liver Function Changes in Laboratory and Prognostic Markers on Sarcopenic Patients with Liver Cirrhosis (BCAAS Study): A Rand. *Front. Nutr.* **2021**, *8*, 715795. [[CrossRef](#)]
234. Mohta, S.; Anand, A.; Sharma, S.; Qamar, S.; Agarwal, S.; Gunjan, D.; Singh, N.; Madhusudhan, K.S.; Pandey, R.M.; Saraya, A. Randomised Clinical Trial: Effect of Adding Branched Chain Amino Acids to Exercise and Standard-of-Care on Muscle Mass in Cirrhotic Patients with Sarcopenia. *Hepatol. Int.* **2022**, *16*, 680–690. [[CrossRef](#)]
235. Ismaiel, A.; Bucsa, C.; Farcas, A.; Leucuta, D.-C.; Popa, S.-L.; Dumitrascu, D.L. Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia in Liver Cirrhosis: Systematic Review and Meta-Analysis. *Front. Nutr.* **2022**, *9*, 749969. [[CrossRef](#)]
236. Johnston, H.E.; Takefala, T.G.; Kelly, J.T.; Keating, S.E.; Coombes, J.S.; Macdonald, G.A.; Hickman, I.J.; Mayr, H.L. The Effect of Diet and Exercise Interventions on Body Composition in Liver Cirrhosis: A Systematic Review. *Nutrients* **2022**, *14*, 3365. [[CrossRef](#)]
237. Casciola, R.; Leoni, L.; Cuffari, B.; Pecchini, M.; Menozzi, R.; Colecchia, A.; Ravaioli, F. Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives. *Nutrients* **2023**, *15*, 863. [[CrossRef](#)] [[PubMed](#)]
238. Lattanzi, B.; Bruni, A.; Di Cola, S.; Molfino, A.; De Santis, A.; Muscaritoli, M.; Merli, M. The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study. *Nutrients* **2021**, *13*, 2296. [[CrossRef](#)] [[PubMed](#)]
239. Espina, S.; Sanz-Paris, A.; Gonzalez-Irazabal, Y.; Pérez-Matute, P.; Andrade, F.; Garcia-Rodriguez, B.; Carpené, C.; Zakaroff, A.; Bernal-Monterde, V.; Fuentes-Olmo, J.; et al. Randomized Clinical Trial: Effects of  $\beta$ -Hydroxy- $\beta$ -Methylbutyrate (HMB)-Enriched vs. HMB-Free Oral Nutritional Supplementation in Malnourished Cirrhotic Patients. *Nutrients* **2022**, *14*, 2344. [[CrossRef](#)]
240. Malaguarnera, M.; Vacante, M.; Motta, M.; Giordano, M.; Malaguarnera, G.; Bella, R.; Nunnari, G.; Rampello, L.; Pennisi, G. Acetyl-L-Carnitine Improves Cognitive Functions in Severe Hepatic Encephalopathy: A Randomized and Controlled Clinical Trial. *Metab. Brain Dis.* **2011**, *26*, 281–289. [[CrossRef](#)]
241. Ohara, M.; Ogawa, K.; Suda, G.; Kimura, M.; Maehara, O.; Shimazaki, T.; Suzuki, K.; Nakamura, A.; Umemura, M.; Izumi, T.; et al. L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients with Liver Cirrhosis. *Hepatol. Commun.* **2018**, *2*, 906–918. [[CrossRef](#)] [[PubMed](#)]
242. Ohashi, K.; Ishikawa, T.; Hoshii, A.; Hokari, T.; Suzuki, M.; Noguchi, H.; Hirose, H.; Koyama, F.; Kobayashi, M.; Hirose, S.; et al. Effect of Levocarnitine Administration in Patients with Chronic Liver Disease. *Exp. Ther. Med.* **2020**, *20*, 94. [[CrossRef](#)] [[PubMed](#)]
243. Hiramatsu, A.; Aikata, H.; Uchikawa, S.; Ohya, K.; Kodama, K.; Nishida, Y.; Daijo, K.; Osawa, M.; Teraoka, Y.; Honda, F.; et al. Levocarnitine Use Is Associated with Improvement in Sarcopenia in Patients with Liver Cirrhosis. *Hepatol. Commun.* **2019**, *3*, 348–355. [[CrossRef](#)] [[PubMed](#)]
244. Hiraoka, A.; Kiguchi, D.; Ninomiya, T.; Hirooka, M.; Abe, M.; Matsuura, B.; Hiasa, Y.; Michitaka, K. Can L-Carnitine Supplementation and Exercise Improve Muscle Complications in Patients with Liver Cirrhosis Who Receive Branched-Chain Amino Acid Supplementation? *Eur. J. Gastroenterol. Hepatol.* **2019**, *31*, 878–884. [[CrossRef](#)]
245. Arai, T.; Atsukawa, M.; Tsubota, A.; Koeda, M.; Yoshida, Y.; Okubo, T.; Nakagawa, A.; Itokawa, N.; Kondo, C.; Nakatsuka, K.; et al. Association of Vitamin D Levels and Vitamin D-Related Gene Polymorphisms with Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. *Dig. Liver Dis.* **2019**, *51*, 1036–1042. [[CrossRef](#)] [[PubMed](#)]
246. Atsukawa, M.; Tsubota, A.; Shimada, N.; Yoshizawa, K.; Abe, H.; Asano, T.; Ohkubo, Y.; Araki, M.; Ikegami, T.; Kondo, C.; et al. Influencing Factors on Serum 25-Hydroxyvitamin D3 Levels in Japanese Chronic Hepatitis C Patients. *BMC Infect. Dis.* **2015**, *15*, 344. [[CrossRef](#)]
247. Okubo, T.; Atsukawa, M.; Tsubota, A.; Yoshida, Y.; Arai, T.; Iwashita, A.-N.; Itokawa, N.; Kondo, C.; Iwakiri, K. Relationship between Serum Vitamin D Level and Sarcopenia in Chronic Liver Disease. *Hepatol. Res. Off. J. Jpn. Soc. Hepatol.* **2020**, *50*, 588–597. [[CrossRef](#)]
248. Saeki, C.; Kanai, T.; Nakano, M.; Oikawa, T.; Torisu, Y.; Saruta, M.; Tsubota, A. Low Serum 25-Hydroxyvitamin D Levels Are Related to Frailty and Sarcopenia in Patients with Chronic Liver Disease. *Nutrients* **2020**, *12*, 3810. [[CrossRef](#)]



249. Okubo, T.; Atsukawa, M.; Tsubota, A.; Ono, H.; Kawano, T.; Yoshida, Y.; Arai, T.; Hayama, K.; Itokawa, N.; Kondo, C.; et al. Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial. *Nutrients* **2021**, *13*, 1874. [[CrossRef](#)]
250. De Spiegeleer, A.; Beckwée, D.; Bautmans, I.; Petrovic, M. Pharmacological Interventions to Improve Muscle Mass, Muscle Strength and Physical Performance in Older People: An Umbrella Review of Systematic Reviews and Meta-Analyses. *Drugs Aging* **2018**, *35*, 719–734. [[CrossRef](#)]
251. Storer, T.W.; Basaria, S.; Traustadottir, T.; Harman, S.M.; Pencina, K.; Li, Z.; Travison, T.G.; Micek, R.; Tsitouras, P.; Hally, K.; et al. Effects of Testosterone Supplementation for 3 Years on Muscle Performance and Physical Function in Older Men. *J. Clin. Endocrinol. Metab.* **2017**, *102*, 583–593. [[CrossRef](#)]
252. Traish, A.M.; Haider, A.; Haider, K.S.; Doros, G.; Saad, F. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups. *J. Cardiovasc. Pharmacol. Ther.* **2017**, *22*, 414–433. [[CrossRef](#)] [[PubMed](#)]
253. Sinclair, M.; Grossmann, M.; Hoermann, R.; Angus, P.W.; Gow, P.J. Testosterone Therapy Increases Muscle Mass in Men with Cirrhosis and Low Testosterone: A Randomised Controlled Trial. *J. Hepatol.* **2016**, *65*, 906–913. [[CrossRef](#)]
254. Associazione Italiana per lo Studio del Fegato (AISF); Società Italiana di Diabetologia (SID); Società Italiana dell’Obesità (SIO). Non-Alcoholic Fatty Liver Disease in Adults 2021: A Clinical Practice Guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). *Eat. Weight Disord.* **2022**, *27*, 1603–1619. [[CrossRef](#)]
255. Petroni, M.L.; Brodosi, L.; Marchignoli, F.; Sasdelli, A.S.; Caraceni, P.; Marchesini, G.; Ravaioli, F. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. *Nutrients* **2021**, *13*, 2748. [[CrossRef](#)]
256. Feike, Y.; Zhijie, L.; Wei, C. Advances in Research on Pharmacotherapy of Sarcopenia. *Aging Med.* **2021**, *4*, 221–233. [[CrossRef](#)] [[PubMed](#)]
257. Sozen, T.; Ozisik, L.; Calik Basaran, N. An Overview and Management of Osteoporosis. *Eur. J. Rheumatol.* **2017**, *4*, 46–56. [[CrossRef](#)]
258. Rossini, M.; Adami, S.; Bertoldo, F.; Diacinti, D.; Gatti, D.; Giannini, S.; Giusti, A.; Malavolta, N.; Minisola, S.; Osella, G.; et al. Guidelines for the Diagnosis, Prevention and Management of Osteoporosis. *Reumatismo* **2016**, *68*, 1–39. [[CrossRef](#)] [[PubMed](#)]
259. Kanis, J.A.; Cooper, C.; Rizzoli, R.; Reginster, J.-Y.; on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European Guidance for the Diagnosis and Management of Osteoporosis in Postmenopausal Women. *Osteoporos. Int.* **2019**, *30*, 3–44. [[CrossRef](#)] [[PubMed](#)]
260. Borgström, F.; Karlsson, L.; Orsäter, G.; Norton, N.; Halbout, P.; Cooper, C.; Lorentzon, M.; McCloskey, E.V.; Harvey, N.C.; Javaid, K.M.; et al. Fragility Fractures in Europe: Burden, Management and Opportunities. *Arch. Osteoporos.* **2020**, *15*, 59. [[CrossRef](#)]
261. WHO, *Prevention and Management of Osteoporosis: Report of a WHO Scientific Group*; WHO Scientific Group Meeting on Prevention and Management of Osteoporosis, Geneva, 7–10 April; Weltgesundheitsorganisation (Ed.) WHO Technical Report Series; World Health Organization: Geneva, Switzerland, 2003; ISBN 978-92-4-120921-2.
262. Compston, J.E.; McClung, M.R.; Leslie, W.D. Osteoporosis. *Lancet* **2019**, *393*, 364–376. [[CrossRef](#)] [[PubMed](#)]
263. Florencio-Silva, R.; da Silva Sasso, G.R.; Sasso-Cerri, E.; Simões, M.J.; Cerri, P.S. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. *BioMed Res. Int.* **2015**, *2015*, 1–17. [[CrossRef](#)]
264. Eshraghian, A. Bone Metabolism in Non-Alcoholic Fatty Liver Disease: Vitamin D Status and Bone Mineral Density. *Minerva Endocrinol* **2017**, *42*, 164–172. [[CrossRef](#)]
265. Ravaioli, F.; Pivetti, A.; Di Marco, L.; Chrysanthi, C.; Frassanito, G.; Pambianco, M.; Sicuro, C.; Gualandi, N.; Guasconi, T.; Pecchini, M.; et al. Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease. *Int. J. Mol. Sci.* **2022**, *23*, 9016. [[CrossRef](#)] [[PubMed](#)]
266. Barchetta, I.; Angelico, F.; Ben, M.D.; Baroni, M.G.; Pozzilli, P.; Morini, S.; Cavallo, M.G. Strong Association between Non Alcoholic Fatty Liver Disease (NAFLD) and Low 25(OH) Vitamin D Levels in an Adult Population with Normal Serum Liver Enzymes. *BMC Med.* **2011**, *9*, 85. [[CrossRef](#)]
267. Ju, S.Y.; Jeong, H.S.; Kim, D.H. Blood Vitamin D Status and Metabolic Syndrome in the General Adult Population: A Dose-Response Meta-Analysis. *J. Clin. Endocrinol. Metab.* **2014**, *99*, 1053–1063. [[CrossRef](#)]
268. Pirgon, O.; Bilgin, H.; Tolu, I.; Odabas, D. Correlation of Insulin Sensitivity with Bone Mineral Status in Obese Adolescents with Nonalcoholic Fatty Liver Disease. *Clin. Endocrinol.* **2011**, *75*, 189–195. [[CrossRef](#)] [[PubMed](#)]
269. Cui, R.; Sheng, H.; Rui, X.-F.; Cheng, X.-Y.; Sheng, C.-J.; Wang, J.-Y.; Qu, S. Low Bone Mineral Density in Chinese Adults with Nonalcoholic Fatty Liver Disease. *Int. J. Endocrinol.* **2013**, *2013*, 1–6. [[CrossRef](#)] [[PubMed](#)]
270. Kaya, M.; Işık, D.; Beştaş, R.; Evliyaoglu, O.; Akpolat, V.; Büyükbayram, H.; Kaplan, M.A. Increased Bone Mineral Density in Patients with Nonalcoholic Steatohepatitis. *WJH* **2013**, *5*, 627. [[CrossRef](#)]
271. Lee, S.H.; Yun, J.M.; Kim, S.H.; Seo, Y.G.; Min, H.; Chung, E.; Bae, Y.S.; Ryou, I.S.; Cho, B. Association between Bone Mineral Density and Nonalcoholic Fatty Liver Disease in Korean Adults. *J. Endocrinol. Investig.* **2016**, *39*, 1329–1336. [[CrossRef](#)] [[PubMed](#)]

272. Upala, S.; Jaruvongvanich, V.; Wijarnpreecha, K.; Sanguankeo, A. Nonalcoholic Fatty Liver Disease and Osteoporosis: A Systematic Review and Meta-Analysis. *J. Bone Min. Metab.* **2017**, *35*, 685–693. [[CrossRef](#)]
273. Mantovani, A.; Dauriz, M.; Gatti, D.; Viapiana, O.; Zoppini, G.; Lippi, G.; Byrne, C.D.; Bonnet, F.; Bonora, E.; Targher, G. Systematic Review with Meta-Analysis: Non-Alcoholic Fatty Liver Disease Is Associated with a History of Osteoporotic Fractures but Not with Low Bone Mineral Density. *Aliment. Pharmacol. Ther.* **2019**, *49*, 375–388. [[CrossRef](#)]
274. Pan, B.; Cai, J.; Zhao, P.; Liu, J.; Fu, S.; Jing, G.; Niu, Q.; Li, Q. Relationship between Prevalence and Risk of Osteoporosis or Osteoporotic Fracture with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Osteoporos. Int.* **2022**, *33*, 2275–2286. [[CrossRef](#)]
275. Bedimo, R.; Cutrell, J.; Zhang, S.; Drechsler, H.; Gao, A.; Brown, G.; Farukhi, I.; Castanon, R.; Tebas, P.; Maalouf, N.M. Mechanisms of Bone Disease in HIV and Hepatitis C Virus: Impact of Bone Turnover, Tenofovir Exposure, Sex Steroids and Severity of Liver Disease. *AIDS* **2016**, *30*, 601–608. [[CrossRef](#)]
276. Jeong, H.M.; Kim, D.J. Bone Diseases in Patients with Chronic Liver Disease. *Int J Mol Sci* **2019**, *20*, 4270. [[CrossRef](#)] [[PubMed](#)]
277. Gilbert, L.; He, X.; Farmer, P.; Rubin, J.; Drissi, H.; van Wijnen, A.J.; Lian, J.B.; Stein, G.S.; Nanes, M.S. Expression of the Osteoblast Differentiation Factor RUNX2 (Cbfa1/AML3/Pebp2 $\alpha$ A) Is Inhibited by Tumor Necrosis Factor- $\alpha$  \*. *J. Biol. Chem.* **2002**, *277*, 2695–2701. [[CrossRef](#)]
278. Zhai, T.; Chen, Q.; Xu, J.; Jia, X.; Xia, P. Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults with Non-Alcoholic Fatty Liver Disease, 2005–2014. *Front. Endocrinol.* **2022**, *12*, 825448. [[CrossRef](#)] [[PubMed](#)]
279. Li, M.; Xu, Y.; Xu, M.; Ma, L.; Wang, T.; Liu, Y.; Dai, M.; Chen, Y.; Lu, J.; Liu, J.; et al. Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Osteoporotic Fracture in Middle-Aged and Elderly Chinese. *J. Clin. Endocrinol. Metab.* **2012**, *97*, 2033–2038. [[CrossRef](#)] [[PubMed](#)]
280. Santos, L.A.A.; Romeiro, F.G. Diagnosis and Management of Cirrhosis-Related Osteoporosis. *BioMed Res. Int.* **2016**, *2016*, 1–12. [[CrossRef](#)]
281. Yang, Y.J.; Kim, D.J. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. *Int. J. Mol. Sci.* **2021**, *22*, 2604. [[CrossRef](#)] [[PubMed](#)]
282. Ahn, S.H.; Seo, D.H.; Kim, S.H.; Nam, M.-S.; Hong, S. The Relationship between Fatty Liver Index and Bone Mineral Density in Koreans: KNHANES 2010–2011. *Osteoporos. Int.* **2018**, *29*, 181–190. [[CrossRef](#)] [[PubMed](#)]
283. Eastell, R.; Rosen, C.J.; Black, D.M.; Cheung, A.M.; Murad, M.H.; Shoback, D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol. Metab.* **2019**, *104*, 1595–1622. [[CrossRef](#)]
284. Thoma, C.; Day, C.P.; Trenell, M.I. Lifestyle Interventions for the Treatment of Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review. *J. Hepatol.* **2012**, *56*, 255–266. [[CrossRef](#)]
285. Kleiner, D.E.; Makhlof, H.R. Histology of NAFLD and NASH in Adults and Children. *Clin. Liver Dis.* **2016**, *20*, 293–312. [[CrossRef](#)]
286. Glass, L.M.; Dickson, R.C.; Anderson, J.C.; Suriawinata, A.A.; Putra, J.; Berk, B.S.; Toor, A. Total Body Weight Loss of  $\geq 10\%$  Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis. *Dig. Dis. Sci.* **2015**, *60*, 1024–1030. [[CrossRef](#)]
287. Hannah, W.N.; Harrison, S.A. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. *Dig. Dis. Sci.* **2016**, *61*, 1365–1374. [[CrossRef](#)]
288. Hirschfeld, H.P.; Kinsella, R.; Duque, G. Osteosarcopenia: Where Bone, Muscle, and Fat Collide. *Osteoporos. Int.* **2017**, *28*, 2781–2790. [[CrossRef](#)]
289. Strobe, M.A.; Nigh, P.; Carter, M.I.; Lin, N.; Jiang, J.; Hinton, P.S. Physical Activity–Associated Bone Loading During Adolescence and Young Adulthood Is Positively Associated with Adult Bone Mineral Density in Men. *Am. J. Mens. Health* **2015**, *9*, 442–450. [[CrossRef](#)] [[PubMed](#)]
290. de Kam, D.; Smulders, E.; Weerdesteyn, V.; Smits-Engelsman, B.C.M. Exercise Interventions to Reduce Fall-Related Fractures and Their Risk Factors in Individuals with Low Bone Density: A Systematic Review of Randomized Controlled Trials. *Osteoporos. Int.* **2009**, *20*, 2111–2125. [[CrossRef](#)] [[PubMed](#)]
291. Russell, R.G.G.; Watts, N.B.; Ebetino, F.H.; Rogers, M.J. Mechanisms of Action of Bisphosphonates: Similarities and Differences and Their Potential Influence on Clinical Efficacy. *Osteoporos. Int.* **2008**, *19*, 733–759. [[CrossRef](#)] [[PubMed](#)]
292. Danford, C.J.; Ezaz, G.; Trivedi, H.D.; Tapper, E.B.; Bonder, A. The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. *J. Clin. Densitom.* **2020**, *23*, 223–236. [[CrossRef](#)] [[PubMed](#)]
293. Zein, C.O.; Jorgensen, R.A.; Clarke, B.; Wenger, D.E.; Keach, J.C.; Angulo, P.; Lindor, K.D. Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis: A Randomized Placebo-Controlled Trial. *Hepatology* **2005**, *42*, 762–771. [[CrossRef](#)]
294. Guañabens, N. Alendronate Is More Effective than Etidronate for Increasing Bone Mass in Osteopenic Patients with Primary Biliary Cirrhosis. *Am. J. Gastroenterol.* **2003**, *98*, 2268–2274. [[CrossRef](#)] [[PubMed](#)]
295. Guañabens, N.; Monegal, A.; Cerdá, D.; Muxí, Á.; Gifre, L.; Peris, P.; Parés, A. Randomized Trial Comparing Monthly Ibandronate and Weekly Alendronate for Osteoporosis in Patients with Primary Biliary Cirrhosis: HEPATOLOGY, Vol. 00, No. X, 2013 GUAÑABENS ET AL. *Hepatology* **2013**, *58*, 2070–2078. [[CrossRef](#)] [[PubMed](#)]

296. Bansal, R.K.; Kumar, M.; Sachdeva, P.R.M.; Kumar, A. Prospective Study of Profile of Hepatic Osteodystrophy in Patients with Non-cholestatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation. *United Eur. Gastroenterol. J.* **2016**, *4*, 77–83. [[CrossRef](#)]
297. Renzulli, M.; Dajti, E.; Ierardi, A.M.; Brandi, N.; Berzigotti, A.; Milandri, M.; Rossini, B.; Clemente, A.; Ravaoli, F.; Marasco, G.; et al. Validation of a Standardized CT Protocol for the Evaluation of Varices and Porto-Systemic Shunts in Cirrhotic Patients. *Eur. J. Radiol.* **2022**, *147*, 110010. [[CrossRef](#)]
298. Lima, T.B.; Santos, L.A.A.; de Carvalho Nunes, H.R.; Silva, G.F.; Caramori, C.A.; Qi, X.; Romeiro, F.G. Safety and Efficacy of Risedronate for Patients with Esophageal Varices and Liver Cirrhosis: A Non-Randomized Clinical Trial. *Sci. Rep.* **2019**, *9*, 18958. [[CrossRef](#)]
299. Santos, L.A.A.; Lima, T.B.; de Carvalho Nunes, H.R.; Qi, X.; Romeiro, F.G. Two-Year Risedronate Treatment for Osteoporosis in Patients with Esophageal Varices: A Non-Randomized Clinical Trial. *Hepatol. Int.* **2022**, *16*, 1458–1467. [[CrossRef](#)]
300. Deeks, E.D. Denosumab: A Review in Postmenopausal Osteoporosis. *Drugs Aging* **2018**, *35*, 163–173. [[CrossRef](#)]
301. Baron, R.; Ferrari, S.; Russell, R.G.G. Denosumab and Bisphosphonates: Different Mechanisms of Action and Effects. *Bone* **2011**, *48*, 677–692. [[CrossRef](#)]
302. Saeki, C.; Saito, M.; Oikawa, T.; Nakano, M.; Torisu, Y.; Saruta, M.; Tsubota, A. Effects of Denosumab Treatment in Chronic Liver Disease Patients with Osteoporosis. *WJG* **2020**, *26*, 4960–4971. [[CrossRef](#)]
303. Polyzos, S.A.; Goulas, A. Treatment of Nonalcoholic Fatty Liver Disease with an Anti-Osteoporotic Medication: A Hypothesis on Drug Repurposing. *Med. Hypotheses* **2021**, *146*, 110379. [[CrossRef](#)] [[PubMed](#)]
304. Vachliotis, I.D.; Anastasilakis, A.D.; Goulas, A.; Goulis, D.G.; Polyzos, S.A. Nonalcoholic Fatty Liver Disease and Osteoporosis: A Potential Association with Therapeutic Implications. *Diabetes Obes. Metab.* **2022**, *24*, 1702–1720. [[CrossRef](#)]
305. Takeno, A.; Yamamoto, M.; Notsu, M.; Sugimoto, T. Administration of Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) Antibody for the Treatment of Osteoporosis Was Associated with Amelioration of Hepatitis in a Female Patient with Growth Hormone Deficiency: A Case Report. *BMC Endocr. Disord.* **2016**, *16*, 66. [[CrossRef](#)] [[PubMed](#)]
306. Reid, I.R.; Billington, E.O. Drug Therapy for Osteoporosis in Older Adults. *Lancet* **2022**, *399*, 1080–1092. [[CrossRef](#)]
307. Polyzos, S.A.; Kang, E.S.; Boutari, C.; Rhee, E.-J.; Mantzoros, C.S. Current and Emerging Pharmacological Options for the Treatment of Nonalcoholic Steatohepatitis. *Metab. Clin. Exp.* **2020**, *111*, 154203. [[CrossRef](#)] [[PubMed](#)]
308. Polyzos, S.A.; Mantzoros, C.S. Adiponectin as a Target for the Treatment of Nonalcoholic Steatohepatitis with Thiazolidinediones: A Systematic Review. *Metab. Clin. Exp.* **2016**, *65*, 1297–1306. [[CrossRef](#)]
309. Pavlova, V.; Filipova, E.; Uzunova, K.; Kalinov, K.; Vekov, T. Pioglitazone Therapy and Fractures: Systematic Review and Meta-Analysis. *EMDDT* **2018**, *18*, 502–507. [[CrossRef](#)]
310. Xie, B.; Chen, S.; Xu, Y.; Han, W.; Hu, R.; Chen, M.; Zhang, Y.; Ding, S. The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment. *Front. Pharmacol.* **2021**, *12*, 697442. [[CrossRef](#)]
311. Cai, T.; Li, H.; Jiang, L.; Wang, H.; Luo, M.; Su, X.; Ma, J. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study. *Biomed. Res. Int.* **2021**, *2021*, 3361309. [[CrossRef](#)]
312. Colosimo, S.; Ravaoli, F.; Petroni, M.L.; Brodosi, L.; Marchignoli, F.; Barbanti, F.A.; Sasdelli, A.S.; Marchesini, G.; Pironi, L. Effects of Antidiabetic Agents on Steatosis and Fibrosis Biomarkers in Type 2 Diabetes: A Real-World Data Analysis. *Liver Int.* **2021**, *41*, 731–742. [[CrossRef](#)] [[PubMed](#)]
313. Kong, Q.; Ruan, Q.; Fan, C.; Liu, B.-L.; Reng, L.-P.; Xu, W. Evaluation of the Risk of Fracture in Type 2 Diabetes Mellitus Patients with Incretins: An Updated Meta-Analysis. *Endokrynol. Pol.* **2021**, *72*, 319–328. [[CrossRef](#)] [[PubMed](#)]
314. Cheng, L.; Hu, Y.; Li, Y.; Cao, X.; Bai, N.; Lu, T.; Li, G.; Li, N.; Wang, A.; Mao, X. Glucagon-like Peptide-1 Receptor Agonists and Risk of Bone Fracture in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. *Diabetes Metab. Res. Rev.* **2019**, *35*, e3168. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.